id	sid	tid	token	lemma	pos
cord-324690-82qsirnk	1	1	key	key	JJ
cord-324690-82qsirnk	1	2	:	:	:
cord-324690-82qsirnk	1	3	cord-324690	cord-324690	NNP
cord-324690-82qsirnk	1	4	-	-	HYPH
cord-324690-82qsirnk	1	5	82qsirnk	82qsirnk	NN
cord-324690-82qsirnk	1	6	authors	author	NNS
cord-324690-82qsirnk	1	7	:	:	:
cord-324690-82qsirnk	1	8	Dieffenbach	Dieffenbach	NNP
cord-324690-82qsirnk	1	9	,	,	,
cord-324690-82qsirnk	1	10	Carl	Carl	NNP
cord-324690-82qsirnk	1	11	W	W	NNP
cord-324690-82qsirnk	1	12	;	;	:
cord-324690-82qsirnk	1	13	Fauci	Fauci	NNP
cord-324690-82qsirnk	1	14	,	,	,
cord-324690-82qsirnk	1	15	Anthony	Anthony	NNP
cord-324690-82qsirnk	1	16	S	S	NNP
cord-324690-82qsirnk	1	17	title	title	NN
cord-324690-82qsirnk	1	18	:	:	:
cord-324690-82qsirnk	2	1	The	the	DT
cord-324690-82qsirnk	2	2	search	search	NN
cord-324690-82qsirnk	2	3	for	for	IN
cord-324690-82qsirnk	2	4	an	an	DT
cord-324690-82qsirnk	2	5	HIV	HIV	NNP
cord-324690-82qsirnk	2	6	vaccine	vaccine	NN
cord-324690-82qsirnk	2	7	,	,	,
cord-324690-82qsirnk	2	8	the	the	DT
cord-324690-82qsirnk	2	9	journey	journey	NN
cord-324690-82qsirnk	2	10	continues	continue	VBZ
cord-324690-82qsirnk	2	11	date	date	NN
cord-324690-82qsirnk	2	12	:	:	:
cord-324690-82qsirnk	2	13	2020	2020	CD
cord-324690-82qsirnk	2	14	-	-	HYPH
cord-324690-82qsirnk	2	15	05	05	CD
cord-324690-82qsirnk	2	16	-	-	HYPH
cord-324690-82qsirnk	2	17	16	16	CD
cord-324690-82qsirnk	2	18	journal	journal	NN
cord-324690-82qsirnk	2	19	:	:	:
cord-324690-82qsirnk	3	1	J	J	NNP
cord-324690-82qsirnk	3	2	Int	Int	NNP
cord-324690-82qsirnk	3	3	AIDS	AIDS	NNP
cord-324690-82qsirnk	3	4	Soc	Soc	NNP
cord-324690-82qsirnk	3	5	DOI	doi	NN
cord-324690-82qsirnk	3	6	:	:	:
cord-324690-82qsirnk	3	7	10.1002/	10.1002/	CD
cord-324690-82qsirnk	4	1	jia2.25506	jia2.25506	NNP
cord-324690-82qsirnk	4	2	sha	sha	NNP
cord-324690-82qsirnk	4	3	:	:	:
cord-324690-82qsirnk	5	1	894a91c603e429e310d7218d6a52cdef54ec0676	894a91c603e429e310d7218d6a52cdef54ec0676	NNP
cord-324690-82qsirnk	5	2	doc_id	doc_id	NNP
cord-324690-82qsirnk	5	3	:	:	:
cord-324690-82qsirnk	6	1	324690	324690	CD
cord-324690-82qsirnk	6	2	cord_uid	cord_uid	NN
cord-324690-82qsirnk	6	3	:	:	:
cord-324690-82qsirnk	7	1	82qsirnk	82qsirnk	NNP
cord-324690-82qsirnk	7	2	nan	nan	NNP
cord-324690-82qsirnk	8	1	As	as	IN
cord-324690-82qsirnk	8	2	we	-PRON-	PRP
cord-324690-82qsirnk	8	3	commemorate	commemorate	VBP
cord-324690-82qsirnk	8	4	HIV	HIV	NNP
cord-324690-82qsirnk	8	5	Vaccine	Vaccine	NNP
cord-324690-82qsirnk	8	6	Awareness	Awareness	NNP
cord-324690-82qsirnk	8	7	Day	Day	NNP
cord-324690-82qsirnk	8	8	,	,	,
cord-324690-82qsirnk	8	9	we	-PRON-	PRP
cord-324690-82qsirnk	8	10	honour	honour	VBP
cord-324690-82qsirnk	8	11	the	the	DT
cord-324690-82qsirnk	8	12	thousands	thousand	NNS
cord-324690-82qsirnk	8	13	of	of	IN
cord-324690-82qsirnk	8	14	study	study	NN
cord-324690-82qsirnk	8	15	participants	participant	NNS
cord-324690-82qsirnk	8	16	and	and	CC
cord-324690-82qsirnk	8	17	the	the	DT
cord-324690-82qsirnk	8	18	research	research	NN
cord-324690-82qsirnk	8	19	teams	team	NNS
cord-324690-82qsirnk	8	20	that	that	WDT
cord-324690-82qsirnk	8	21	have	have	VBP
cord-324690-82qsirnk	8	22	played	play	VBN
cord-324690-82qsirnk	8	23	essential	essential	JJ
cord-324690-82qsirnk	8	24	roles	role	NNS
cord-324690-82qsirnk	8	25	in	in	IN
cord-324690-82qsirnk	8	26	the	the	DT
cord-324690-82qsirnk	8	27	completed	complete	VBN
cord-324690-82qsirnk	8	28	and	and	CC
cord-324690-82qsirnk	8	29	ongoing	ongoing	JJ
cord-324690-82qsirnk	8	30	vaccine	vaccine	NN
cord-324690-82qsirnk	8	31	clinical	clinical	JJ
cord-324690-82qsirnk	8	32	trials	trial	NNS
cord-324690-82qsirnk	8	33	.	.	.
cord-324690-82qsirnk	9	1	We	-PRON-	PRP
cord-324690-82qsirnk	9	2	also	also	RB
cord-324690-82qsirnk	9	3	recognize	recognize	VBP
cord-324690-82qsirnk	9	4	the	the	DT
cord-324690-82qsirnk	9	5	scientists	scientist	NNS
cord-324690-82qsirnk	9	6	who	who	WP
cord-324690-82qsirnk	9	7	have	have	VBP
cord-324690-82qsirnk	9	8	spent	spend	VBN
cord-324690-82qsirnk	9	9	years	year	NNS
cord-324690-82qsirnk	9	10	dedicated	dedicate	VBN
cord-324690-82qsirnk	9	11	to	to	IN
cord-324690-82qsirnk	9	12	creating	create	VBG
cord-324690-82qsirnk	9	13	the	the	DT
cord-324690-82qsirnk	9	14	tools	tool	NNS
cord-324690-82qsirnk	9	15	and	and	CC
cord-324690-82qsirnk	9	16	technologies	technology	NNS
cord-324690-82qsirnk	9	17	to	to	TO
cord-324690-82qsirnk	9	18	end	end	VB
cord-324690-82qsirnk	9	19	the	the	DT
cord-324690-82qsirnk	9	20	global	global	JJ
cord-324690-82qsirnk	9	21	HIV	HIV	NNP
cord-324690-82qsirnk	9	22	epidemic	epidemic	NN
cord-324690-82qsirnk	9	23	.	.	.
cord-324690-82qsirnk	10	1	On	on	IN
cord-324690-82qsirnk	10	2	this	this	DT
cord-324690-82qsirnk	10	3	Vaccine	Vaccine	NNP
cord-324690-82qsirnk	10	4	Awareness	Awareness	NNP
cord-324690-82qsirnk	10	5	Day	Day	NNP
cord-324690-82qsirnk	10	6	,	,	,
cord-324690-82qsirnk	10	7	we	-PRON-	PRP
cord-324690-82qsirnk	10	8	must	must	MD
cord-324690-82qsirnk	10	9	acknowledge	acknowledge	VB
cord-324690-82qsirnk	10	10	that	that	IN
cord-324690-82qsirnk	10	11	the	the	DT
cord-324690-82qsirnk	10	12	HIV	HIV	NNP
cord-324690-82qsirnk	10	13	vaccine	vaccine	NN
cord-324690-82qsirnk	10	14	research	research	NN
cord-324690-82qsirnk	10	15	field	field	NN
cord-324690-82qsirnk	10	16	is	be	VBZ
cord-324690-82qsirnk	10	17	quickly	quickly	RB
cord-324690-82qsirnk	10	18	approaching	approach	VBG
cord-324690-82qsirnk	10	19	a	a	DT
cord-324690-82qsirnk	10	20	critical	critical	JJ
cord-324690-82qsirnk	10	21	crossroads	crossroad	NNS
cord-324690-82qsirnk	10	22	.	.	.
cord-324690-82qsirnk	11	1	This	this	DT
cord-324690-82qsirnk	11	2	past	past	JJ
cord-324690-82qsirnk	11	3	decade	decade	NN
cord-324690-82qsirnk	11	4	has	have	VBZ
cord-324690-82qsirnk	11	5	been	be	VBN
cord-324690-82qsirnk	11	6	spent	spend	VBN
cord-324690-82qsirnk	11	7	launching	launch	VBG
cord-324690-82qsirnk	11	8	improved	improve	VBN
cord-324690-82qsirnk	11	9	vaccine	vaccine	NN
cord-324690-82qsirnk	11	10	concepts	concept	NNS
cord-324690-82qsirnk	11	11	and	and	CC
cord-324690-82qsirnk	11	12	immune	immune	NN
cord-324690-82qsirnk	11	13	-	-	HYPH
cord-324690-82qsirnk	11	14	based	base	VBN
cord-324690-82qsirnk	11	15	strategies	strategy	NNS
cord-324690-82qsirnk	11	16	into	into	IN
cord-324690-82qsirnk	11	17	trials	trial	NNS
cord-324690-82qsirnk	11	18	.	.	.
cord-324690-82qsirnk	12	1	Despite	despite	IN
cord-324690-82qsirnk	12	2	these	these	DT
cord-324690-82qsirnk	12	3	advances	advance	NNS
cord-324690-82qsirnk	12	4	,	,	,
cord-324690-82qsirnk	12	5	a	a	DT
cord-324690-82qsirnk	12	6	safe	safe	JJ
cord-324690-82qsirnk	12	7	and	and	CC
cord-324690-82qsirnk	12	8	durably	durably	RB
cord-324690-82qsirnk	12	9	effective	effective	JJ
cord-324690-82qsirnk	12	10	HIV	HIV	NNP
cord-324690-82qsirnk	12	11	vaccine	vaccine	NN
cord-324690-82qsirnk	12	12	has	have	VBZ
cord-324690-82qsirnk	12	13	eluded	elude	VBN
cord-324690-82qsirnk	12	14	us	-PRON-	PRP
cord-324690-82qsirnk	12	15	.	.	.
cord-324690-82qsirnk	13	1	In	in	IN
cord-324690-82qsirnk	13	2	this	this	DT
cord-324690-82qsirnk	13	3	regard	regard	NN
cord-324690-82qsirnk	13	4	,	,	,
cord-324690-82qsirnk	13	5	we	-PRON-	PRP
cord-324690-82qsirnk	13	6	must	must	MD
cord-324690-82qsirnk	13	7	evaluate	evaluate	VB
cord-324690-82qsirnk	13	8	the	the	DT
cord-324690-82qsirnk	13	9	current	current	JJ
cord-324690-82qsirnk	13	10	state	state	NN
cord-324690-82qsirnk	13	11	of	of	IN
cord-324690-82qsirnk	13	12	the	the	DT
cord-324690-82qsirnk	13	13	field	field	NN
cord-324690-82qsirnk	13	14	and	and	CC
cord-324690-82qsirnk	13	15	make	make	VB
cord-324690-82qsirnk	13	16	appropriate	appropriate	JJ
cord-324690-82qsirnk	13	17	adjustments	adjustment	NNS
cord-324690-82qsirnk	13	18	to	to	TO
cord-324690-82qsirnk	13	19	help	help	VB
cord-324690-82qsirnk	13	20	speed	speed	VB
cord-324690-82qsirnk	13	21	us	-PRON-	PRP
cord-324690-82qsirnk	13	22	to	to	IN
cord-324690-82qsirnk	13	23	our	-PRON-	PRP$
cord-324690-82qsirnk	13	24	goal	goal	NN
cord-324690-82qsirnk	13	25	.	.	.
cord-324690-82qsirnk	14	1	While	while	IN
cord-324690-82qsirnk	14	2	this	this	DT
cord-324690-82qsirnk	14	3	quest	quest	NN
cord-324690-82qsirnk	14	4	for	for	IN
cord-324690-82qsirnk	14	5	a	a	DT
cord-324690-82qsirnk	14	6	vaccine	vaccine	NN
cord-324690-82qsirnk	14	7	at	at	IN
cord-324690-82qsirnk	14	8	times	time	NNS
cord-324690-82qsirnk	14	9	may	may	MD
cord-324690-82qsirnk	14	10	feel	feel	VB
cord-324690-82qsirnk	14	11	extremely	extremely	RB
cord-324690-82qsirnk	14	12	difficult	difficult	JJ
cord-324690-82qsirnk	14	13	,	,	,
cord-324690-82qsirnk	14	14	as	as	IN
cord-324690-82qsirnk	14	15	evidenced	evidence	VBN
cord-324690-82qsirnk	14	16	by	by	IN
cord-324690-82qsirnk	14	17	the	the	DT
cord-324690-82qsirnk	14	18	recent	recent	JJ
cord-324690-82qsirnk	14	19	disappointing	disappointing	JJ
cord-324690-82qsirnk	14	20	results	result	NNS
cord-324690-82qsirnk	14	21	of	of	IN
cord-324690-82qsirnk	14	22	a	a	DT
cord-324690-82qsirnk	14	23	phase	phase	NN
cord-324690-82qsirnk	14	24	III	iii	CD
cord-324690-82qsirnk	14	25	efficacy	efficacy	NN
cord-324690-82qsirnk	14	26	trial	trial	NN
cord-324690-82qsirnk	14	27	,	,	,
cord-324690-82qsirnk	14	28	HVTN	HVTN	NNP
cord-324690-82qsirnk	14	29	702	702	NNP
cord-324690-82qsirnk	14	30	,	,	,
cord-324690-82qsirnk	14	31	described	describe	VBN
cord-324690-82qsirnk	14	32	below	below	RB
cord-324690-82qsirnk	14	33	,	,	,
cord-324690-82qsirnk	14	34	we	-PRON-	PRP
cord-324690-82qsirnk	14	35	must	must	MD
cord-324690-82qsirnk	14	36	steadfastly	steadfastly	RB
cord-324690-82qsirnk	14	37	move	move	VB
cord-324690-82qsirnk	14	38	forward	forward	RB
cord-324690-82qsirnk	14	39	to	to	TO
cord-324690-82qsirnk	14	40	address	address	VB
cord-324690-82qsirnk	14	41	critical	critical	JJ
cord-324690-82qsirnk	14	42	research	research	NN
cord-324690-82qsirnk	14	43	gaps	gap	NNS
cord-324690-82qsirnk	14	44	and	and	CC
cord-324690-82qsirnk	14	45	unanswered	unanswered	JJ
cord-324690-82qsirnk	14	46	questions	question	NNS
cord-324690-82qsirnk	14	47	.	.	.
cord-324690-82qsirnk	15	1	As	as	IN
cord-324690-82qsirnk	15	2	we	-PRON-	PRP
cord-324690-82qsirnk	15	3	reflect	reflect	VBP
cord-324690-82qsirnk	15	4	upon	upon	IN
cord-324690-82qsirnk	15	5	the	the	DT
cord-324690-82qsirnk	15	6	status	status	NN
cord-324690-82qsirnk	15	7	of	of	IN
cord-324690-82qsirnk	15	8	HIV	HIV	NNP
cord-324690-82qsirnk	15	9	vaccine	vaccine	NN
cord-324690-82qsirnk	15	10	research	research	NN
cord-324690-82qsirnk	15	11	,	,	,
cord-324690-82qsirnk	15	12	we	-PRON-	PRP
cord-324690-82qsirnk	15	13	would	would	MD
cord-324690-82qsirnk	15	14	be	be	VB
cord-324690-82qsirnk	15	15	remiss	remiss	JJ
cord-324690-82qsirnk	15	16	if	if	IN
cord-324690-82qsirnk	15	17	we	-PRON-	PRP
cord-324690-82qsirnk	15	18	did	do	VBD
cord-324690-82qsirnk	15	19	not	not	RB
cord-324690-82qsirnk	15	20	mention	mention	VB
cord-324690-82qsirnk	15	21	the	the	DT
cord-324690-82qsirnk	15	22	current	current	JJ
cord-324690-82qsirnk	15	23	global	global	JJ
cord-324690-82qsirnk	15	24	pandemic	pandemic	NN
cord-324690-82qsirnk	15	25	caused	cause	VBN
cord-324690-82qsirnk	15	26	by	by	IN
cord-324690-82qsirnk	15	27	SARS	SARS	NNP
cord-324690-82qsirnk	15	28	-	-	HYPH
cord-324690-82qsirnk	15	29	CoV-2	CoV-2	NNP
cord-324690-82qsirnk	15	30	.	.	.
cord-324690-82qsirnk	16	1	It	-PRON-	PRP
cord-324690-82qsirnk	16	2	is	be	VBZ
cord-324690-82qsirnk	16	3	important	important	JJ
cord-324690-82qsirnk	16	4	to	to	TO
cord-324690-82qsirnk	16	5	acknowledge	acknowledge	VB
cord-324690-82qsirnk	16	6	the	the	DT
cord-324690-82qsirnk	16	7	global	global	JJ
cord-324690-82qsirnk	16	8	response	response	NN
cord-324690-82qsirnk	16	9	to	to	IN
cord-324690-82qsirnk	16	10	the	the	DT
cord-324690-82qsirnk	16	11	COVID-19	covid-19	JJ
cord-324690-82qsirnk	16	12	epidemic	epidemic	NN
cord-324690-82qsirnk	16	13	and	and	CC
cord-324690-82qsirnk	16	14	to	to	TO
cord-324690-82qsirnk	16	15	cite	cite	VB
cord-324690-82qsirnk	16	16	the	the	DT
cord-324690-82qsirnk	16	17	range	range	NN
cord-324690-82qsirnk	16	18	of	of	IN
cord-324690-82qsirnk	16	19	vaccine	vaccine	NN
cord-324690-82qsirnk	16	20	platforms	platform	NNS
cord-324690-82qsirnk	16	21	being	be	VBG
cord-324690-82qsirnk	16	22	used	use	VBN
cord-324690-82qsirnk	16	23	for	for	IN
cord-324690-82qsirnk	16	24	anti	anti	JJ
cord-324690-82qsirnk	16	25	-	-	JJ
cord-324690-82qsirnk	16	26	SARS	SARS	NNP
cord-324690-82qsirnk	16	27	-	-	HYPH
cord-324690-82qsirnk	16	28	CoV-2	CoV-2	NNP
cord-324690-82qsirnk	16	29	candidate	candidate	NN
cord-324690-82qsirnk	16	30	vaccines	vaccine	NNS
cord-324690-82qsirnk	16	31	that	that	WDT
cord-324690-82qsirnk	16	32	have	have	VBP
cord-324690-82qsirnk	16	33	their	-PRON-	PRP$
cord-324690-82qsirnk	16	34	origin	origin	NN
cord-324690-82qsirnk	16	35	in	in	IN
cord-324690-82qsirnk	16	36	HIV	HIV	NNP
cord-324690-82qsirnk	16	37	vaccinology	vaccinology	NN
cord-324690-82qsirnk	16	38	.	.	.
cord-324690-82qsirnk	17	1	The	the	DT
cord-324690-82qsirnk	17	2	HIV	HIV	NNP
cord-324690-82qsirnk	17	3	vaccine	vaccine	NN
cord-324690-82qsirnk	17	4	field	field	NN
cord-324690-82qsirnk	17	5	is	be	VBZ
cord-324690-82qsirnk	17	6	clearly	clearly	RB
cord-324690-82qsirnk	17	7	assisting	assist	VBG
cord-324690-82qsirnk	17	8	in	in	IN
cord-324690-82qsirnk	17	9	addressing	address	VBG
cord-324690-82qsirnk	17	10	this	this	DT
cord-324690-82qsirnk	17	11	newly	newly	RB
cord-324690-82qsirnk	17	12	emergent	emergent	JJ
cord-324690-82qsirnk	17	13	pandemic	pandemic	NN
cord-324690-82qsirnk	17	14	and	and	CC
cord-324690-82qsirnk	17	15	the	the	DT
cord-324690-82qsirnk	17	16	National	National	NNP
cord-324690-82qsirnk	17	17	Institute	Institute	NNP
cord-324690-82qsirnk	17	18	of	of	IN
cord-324690-82qsirnk	17	19	Allergy	Allergy	NNP
cord-324690-82qsirnk	17	20	and	and	CC
cord-324690-82qsirnk	17	21	Infectious	Infectious	NNP
cord-324690-82qsirnk	17	22	Diseases	Diseases	NNPS
cord-324690-82qsirnk	17	23	(	(	-LRB-
cord-324690-82qsirnk	17	24	NIAID	NIAID	NNP
cord-324690-82qsirnk	17	25	)	)	-RRB-
cord-324690-82qsirnk	18	1	is	be	VBZ
cord-324690-82qsirnk	18	2	fostering	foster	VBG
cord-324690-82qsirnk	18	3	these	these	DT
cord-324690-82qsirnk	18	4	essential	essential	JJ
cord-324690-82qsirnk	18	5	collaborations	collaboration	NNS
cord-324690-82qsirnk	18	6	.	.	.
cord-324690-82qsirnk	19	1	For	for	IN
cord-324690-82qsirnk	19	2	HIV	HIV	NNP
cord-324690-82qsirnk	19	3	Vaccine	Vaccine	NNP
cord-324690-82qsirnk	19	4	Awareness	Awareness	NNP
cord-324690-82qsirnk	19	5	Day	Day	NNP
cord-324690-82qsirnk	19	6	in	in	IN
cord-324690-82qsirnk	19	7	2020	2020	CD
cord-324690-82qsirnk	19	8	,	,	,
cord-324690-82qsirnk	19	9	we	-PRON-	PRP
cord-324690-82qsirnk	19	10	emphatically	emphatically	RB
cord-324690-82qsirnk	19	11	state	state	VBP
cord-324690-82qsirnk	19	12	that	that	IN
cord-324690-82qsirnk	19	13	finding	find	VBG
cord-324690-82qsirnk	19	14	safe	safe	JJ
cord-324690-82qsirnk	19	15	,	,	,
cord-324690-82qsirnk	19	16	effective	effective	JJ
cord-324690-82qsirnk	19	17	and	and	CC
cord-324690-82qsirnk	19	18	durable	durable	JJ
cord-324690-82qsirnk	19	19	vaccines	vaccine	NNS
cord-324690-82qsirnk	19	20	for	for	IN
cord-324690-82qsirnk	19	21	HIV	HIV	NNP
cord-324690-82qsirnk	19	22	and	and	CC
cord-324690-82qsirnk	19	23	COVID-19	COVID-19	NNP
cord-324690-82qsirnk	19	24	are	be	VBP
cord-324690-82qsirnk	19	25	NIAID	NIAID	NNP
cord-324690-82qsirnk	19	26	's	's	POS
cord-324690-82qsirnk	19	27	top	top	JJ
cord-324690-82qsirnk	19	28	priorities	priority	NNS
cord-324690-82qsirnk	19	29	.	.	.
cord-324690-82qsirnk	20	1	The	the	DT
cord-324690-82qsirnk	20	2	world	world	NN
cord-324690-82qsirnk	20	3	must	must	MD
cord-324690-82qsirnk	20	4	have	have	VB
cord-324690-82qsirnk	20	5	both	both	DT
cord-324690-82qsirnk	20	6	.	.	.
cord-324690-82qsirnk	21	1	Based	base	VBN
cord-324690-82qsirnk	21	2	upon	upon	IN
cord-324690-82qsirnk	21	3	the	the	DT
cord-324690-82qsirnk	21	4	challenges	challenge	NNS
cord-324690-82qsirnk	21	5	that	that	WDT
cord-324690-82qsirnk	21	6	HIV	HIV	NNP
cord-324690-82qsirnk	21	7	biology	biology	NN
cord-324690-82qsirnk	21	8	presents	present	VBZ
cord-324690-82qsirnk	21	9	:	:	:
cord-324690-82qsirnk	21	10	global	global	JJ
cord-324690-82qsirnk	21	11	sequence	sequence	NN
cord-324690-82qsirnk	21	12	diversity	diversity	NN
cord-324690-82qsirnk	21	13	,	,	,
cord-324690-82qsirnk	21	14	integration	integration	NN
cord-324690-82qsirnk	21	15	of	of	IN
cord-324690-82qsirnk	21	16	the	the	DT
cord-324690-82qsirnk	21	17	viral	viral	JJ
cord-324690-82qsirnk	21	18	genome	genome	NN
cord-324690-82qsirnk	21	19	into	into	IN
cord-324690-82qsirnk	21	20	the	the	DT
cord-324690-82qsirnk	21	21	host	host	NN
cord-324690-82qsirnk	21	22	cells	cell	NNS
cord-324690-82qsirnk	21	23	and	and	CC
cord-324690-82qsirnk	21	24	long	long	JJ
cord-324690-82qsirnk	21	25	duration	duration	NN
cord-324690-82qsirnk	21	26	of	of	IN
cord-324690-82qsirnk	21	27	the	the	DT
cord-324690-82qsirnk	21	28	symptom	symptom	NN
cord-324690-82qsirnk	21	29	free	free	JJ
cord-324690-82qsirnk	21	30	period	period	NN
cord-324690-82qsirnk	21	31	of	of	IN
cord-324690-82qsirnk	21	32	infection	infection	NN
cord-324690-82qsirnk	21	33	as	as	RB
cord-324690-82qsirnk	21	34	well	well	RB
cord-324690-82qsirnk	21	35	as	as	IN
cord-324690-82qsirnk	21	36	the	the	DT
cord-324690-82qsirnk	21	37	fact	fact	NN
cord-324690-82qsirnk	21	38	that	that	IN
cord-324690-82qsirnk	21	39	no	no	DT
cord-324690-82qsirnk	21	40	single	single	JJ
cord-324690-82qsirnk	21	41	individual	individual	NN
cord-324690-82qsirnk	21	42	has	have	VBZ
cord-324690-82qsirnk	21	43	been	be	VBN
cord-324690-82qsirnk	21	44	spontaneously	spontaneously	RB
cord-324690-82qsirnk	21	45	cured	cure	VBN
cord-324690-82qsirnk	21	46	,	,	,
cord-324690-82qsirnk	21	47	it	-PRON-	PRP
cord-324690-82qsirnk	21	48	is	be	VBZ
cord-324690-82qsirnk	21	49	widely	widely	RB
cord-324690-82qsirnk	21	50	accepted	accept	VBN
cord-324690-82qsirnk	21	51	that	that	IN
cord-324690-82qsirnk	21	52	a	a	DT
cord-324690-82qsirnk	21	53	vaccine	vaccine	NN
cord-324690-82qsirnk	21	54	must	must	MD
cord-324690-82qsirnk	21	55	trigger	trigger	VB
cord-324690-82qsirnk	21	56	responses	response	NNS
cord-324690-82qsirnk	21	57	that	that	WDT
cord-324690-82qsirnk	21	58	are	be	VBP
cord-324690-82qsirnk	21	59	qualitatively	qualitatively	RB
cord-324690-82qsirnk	21	60	different	different	JJ
cord-324690-82qsirnk	21	61	from	from	IN
cord-324690-82qsirnk	21	62	the	the	DT
cord-324690-82qsirnk	21	63	immune	immune	JJ
cord-324690-82qsirnk	21	64	responses	response	NNS
cord-324690-82qsirnk	21	65	to	to	IN
cord-324690-82qsirnk	21	66	natural	natural	JJ
cord-324690-82qsirnk	21	67	infection	infection	NN
cord-324690-82qsirnk	21	68	.	.	.
cord-324690-82qsirnk	22	1	After	after	IN
cord-324690-82qsirnk	22	2	the	the	DT
cord-324690-82qsirnk	22	3	STEP	step	NN
cord-324690-82qsirnk	22	4	trial	trial	NN
cord-324690-82qsirnk	22	5	(	(	-LRB-
cord-324690-82qsirnk	22	6	also	also	RB
cord-324690-82qsirnk	22	7	referred	refer	VBN
cord-324690-82qsirnk	22	8	to	to	IN
cord-324690-82qsirnk	22	9	as	as	IN
cord-324690-82qsirnk	22	10	HVTN	HVTN	NNP
cord-324690-82qsirnk	22	11	502	502	CD
cord-324690-82qsirnk	22	12	or	or	CC
cord-324690-82qsirnk	22	13	Merck	Merck	NNP
cord-324690-82qsirnk	22	14	V520	V520	NNP
cord-324690-82qsirnk	22	15	-	-	HYPH
cord-324690-82qsirnk	22	16	023	023	CD
cord-324690-82qsirnk	22	17	)	)	-RRB-
cord-324690-82qsirnk	22	18	was	be	VBD
cord-324690-82qsirnk	22	19	halted	halt	VBN
cord-324690-82qsirnk	22	20	in	in	IN
cord-324690-82qsirnk	22	21	2007	2007	CD
cord-324690-82qsirnk	22	22	,	,	,
cord-324690-82qsirnk	22	23	vaccine	vaccine	NN
cord-324690-82qsirnk	22	24	candidates	candidate	NNS
cord-324690-82qsirnk	22	25	that	that	WDT
cord-324690-82qsirnk	22	26	fulfilled	fulfil	VBD
cord-324690-82qsirnk	22	27	these	these	DT
cord-324690-82qsirnk	22	28	criteria	criterion	NNS
cord-324690-82qsirnk	22	29	have	have	VBP
cord-324690-82qsirnk	22	30	been	be	VBN
cord-324690-82qsirnk	22	31	prioritized	prioritize	VBN
cord-324690-82qsirnk	22	32	[	[	-LRB-
cord-324690-82qsirnk	22	33	1	1	CD
cord-324690-82qsirnk	22	34	,	,	,
cord-324690-82qsirnk	22	35	2	2	CD
cord-324690-82qsirnk	22	36	]	]	-RRB-
cord-324690-82qsirnk	22	37	.	.	.
cord-324690-82qsirnk	23	1	Over	over	IN
cord-324690-82qsirnk	23	2	the	the	DT
cord-324690-82qsirnk	23	3	past	past	JJ
cord-324690-82qsirnk	23	4	decade	decade	NN
cord-324690-82qsirnk	23	5	,	,	,
cord-324690-82qsirnk	23	6	three	three	CD
cord-324690-82qsirnk	23	7	different	different	JJ
cord-324690-82qsirnk	23	8	vaccine	vaccine	NN
cord-324690-82qsirnk	23	9	approaches	approach	NNS
cord-324690-82qsirnk	23	10	have	have	VBP
cord-324690-82qsirnk	23	11	been	be	VBN
cord-324690-82qsirnk	23	12	implemented	implement	VBN
cord-324690-82qsirnk	23	13	,	,	,
cord-324690-82qsirnk	23	14	possible	possible	JJ
cord-324690-82qsirnk	23	15	correlates	correlate	NNS
cord-324690-82qsirnk	23	16	of	of	IN
cord-324690-82qsirnk	23	17	protection	protection	NN
cord-324690-82qsirnk	23	18	identified	identify	VBN
cord-324690-82qsirnk	23	19	,	,	,
cord-324690-82qsirnk	23	20	and	and	CC
cord-324690-82qsirnk	23	21	two	two	CD
cord-324690-82qsirnk	23	22	have	have	VBP
cord-324690-82qsirnk	23	23	moved	move	VBN
cord-324690-82qsirnk	23	24	through	through	IN
cord-324690-82qsirnk	23	25	clinical	clinical	JJ
cord-324690-82qsirnk	23	26	evaluation	evaluation	NN
cord-324690-82qsirnk	23	27	to	to	IN
cord-324690-82qsirnk	23	28	advanced	advanced	JJ
cord-324690-82qsirnk	23	29	clinical	clinical	JJ
cord-324690-82qsirnk	23	30	trials	trial	NNS
cord-324690-82qsirnk	23	31	.	.	.
cord-324690-82qsirnk	24	1	The	the	DT
cord-324690-82qsirnk	24	2	first	first	JJ
cord-324690-82qsirnk	24	3	of	of	IN
cord-324690-82qsirnk	24	4	these	these	DT
cord-324690-82qsirnk	24	5	was	be	VBD
cord-324690-82qsirnk	24	6	based	base	VBN
cord-324690-82qsirnk	24	7	upon	upon	IN
cord-324690-82qsirnk	24	8	the	the	DT
cord-324690-82qsirnk	24	9	correlates	correlate	NNS
cord-324690-82qsirnk	24	10	of	of	IN
cord-324690-82qsirnk	24	11	risk	risk	NN
cord-324690-82qsirnk	24	12	that	that	WDT
cord-324690-82qsirnk	24	13	were	be	VBD
cord-324690-82qsirnk	24	14	generated	generate	VBN
cord-324690-82qsirnk	24	15	from	from	IN
cord-324690-82qsirnk	24	16	analysis	analysis	NN
cord-324690-82qsirnk	24	17	of	of	IN
cord-324690-82qsirnk	24	18	the	the	DT
cord-324690-82qsirnk	24	19	RV144	RV144	NNP
cord-324690-82qsirnk	24	20	trial	trial	NN
cord-324690-82qsirnk	24	21	conducted	conduct	VBN
cord-324690-82qsirnk	24	22	in	in	IN
cord-324690-82qsirnk	24	23	Thailand	Thailand	NNP
cord-324690-82qsirnk	24	24	,	,	,
cord-324690-82qsirnk	24	25	which	which	WDT
cord-324690-82qsirnk	24	26	in	in	IN
cord-324690-82qsirnk	24	27	2009	2009	CD
cord-324690-82qsirnk	24	28	,	,	,
cord-324690-82qsirnk	24	29	reported	report	VBD
cord-324690-82qsirnk	24	30	modest	modest	JJ
cord-324690-82qsirnk	24	31	levels	level	NNS
cord-324690-82qsirnk	24	32	of	of	IN
cord-324690-82qsirnk	24	33	efficacy	efficacy	NN
cord-324690-82qsirnk	24	34	[	[	-LRB-
cord-324690-82qsirnk	24	35	3	3	CD
cord-324690-82qsirnk	24	36	,	,	,
cord-324690-82qsirnk	24	37	4	4	CD
cord-324690-82qsirnk	24	38	]	]	-RRB-
cord-324690-82qsirnk	24	39	.	.	.
cord-324690-82qsirnk	25	1	Rather	rather	RB
cord-324690-82qsirnk	25	2	than	than	IN
cord-324690-82qsirnk	25	3	perform	perform	VB
cord-324690-82qsirnk	25	4	a	a	DT
cord-324690-82qsirnk	25	5	direct	direct	JJ
cord-324690-82qsirnk	25	6	repeat	repeat	NN
cord-324690-82qsirnk	25	7	of	of	IN
cord-324690-82qsirnk	25	8	RV144	rv144	NN
cord-324690-82qsirnk	25	9	in	in	IN
cord-324690-82qsirnk	25	10	Thailand	Thailand	NNP
cord-324690-82qsirnk	25	11	,	,	,
cord-324690-82qsirnk	25	12	where	where	WRB
cord-324690-82qsirnk	25	13	the	the	DT
cord-324690-82qsirnk	25	14	epidemic	epidemic	NN
cord-324690-82qsirnk	25	15	is	be	VBZ
cord-324690-82qsirnk	25	16	driven	drive	VBN
cord-324690-82qsirnk	25	17	by	by	IN
cord-324690-82qsirnk	25	18	viruses	virus	NNS
cord-324690-82qsirnk	25	19	from	from	IN
cord-324690-82qsirnk	25	20	clades	clade	NNS
cord-324690-82qsirnk	25	21	AE	AE	NNP
cord-324690-82qsirnk	25	22	and	and	CC
cord-324690-82qsirnk	25	23	B	B	NNP
cord-324690-82qsirnk	25	24	,	,	,
cord-324690-82qsirnk	25	25	a	a	DT
cord-324690-82qsirnk	25	26	clade	clade	NN
cord-324690-82qsirnk	25	27	C	c	NN
cord-324690-82qsirnk	25	28	-	-	HYPH
cord-324690-82qsirnk	25	29	specific	specific	JJ
cord-324690-82qsirnk	25	30	regimen	regimen	NN
cord-324690-82qsirnk	25	31	was	be	VBD
cord-324690-82qsirnk	25	32	developed	develop	VBN
cord-324690-82qsirnk	25	33	for	for	IN
cord-324690-82qsirnk	25	34	testing	testing	NN
cord-324690-82qsirnk	25	35	in	in	IN
cord-324690-82qsirnk	25	36	Southern	Southern	NNP
cord-324690-82qsirnk	25	37	Africa	Africa	NNP
cord-324690-82qsirnk	25	38	.	.	.
cord-324690-82qsirnk	26	1	When	when	WRB
cord-324690-82qsirnk	26	2	evaluated	evaluate	VBN
cord-324690-82qsirnk	26	3	in	in	IN
cord-324690-82qsirnk	26	4	the	the	DT
cord-324690-82qsirnk	26	5	HVTN100	HVTN100	NNP
cord-324690-82qsirnk	26	6	trial	trial	NN
cord-324690-82qsirnk	26	7	,	,	,
cord-324690-82qsirnk	26	8	the	the	DT
cord-324690-82qsirnk	26	9	relevant	relevant	JJ
cord-324690-82qsirnk	26	10	correlate	correlate	VBP
cord-324690-82qsirnk	26	11	responses	response	NNS
cord-324690-82qsirnk	26	12	were	be	VBD
cord-324690-82qsirnk	26	13	detected	detect	VBN
cord-324690-82qsirnk	26	14	and	and	CC
cord-324690-82qsirnk	26	15	shown	show	VBN
cord-324690-82qsirnk	26	16	to	to	TO
cord-324690-82qsirnk	26	17	be	be	VB
cord-324690-82qsirnk	26	18	longer	long	RBR
cord-324690-82qsirnk	26	19	lasting	last	VBG
cord-324690-82qsirnk	26	20	than	than	IN
cord-324690-82qsirnk	26	21	those	those	DT
cord-324690-82qsirnk	26	22	of	of	IN
cord-324690-82qsirnk	26	23	RV144	RV144	NNP
cord-324690-82qsirnk	26	24	[	[	-LRB-
cord-324690-82qsirnk	26	25	5	5	CD
cord-324690-82qsirnk	26	26	]	]	-RRB-
cord-324690-82qsirnk	26	27	[	[	-LRB-
cord-324690-82qsirnk	26	28	6	6	CD
cord-324690-82qsirnk	26	29	]	]	-RRB-
cord-324690-82qsirnk	26	30	[	[	-LRB-
cord-324690-82qsirnk	26	31	7	7	CD
cord-324690-82qsirnk	26	32	]	]	-RRB-
cord-324690-82qsirnk	26	33	.	.	.
cord-324690-82qsirnk	27	1	With	with	IN
cord-324690-82qsirnk	27	2	the	the	DT
cord-324690-82qsirnk	27	3	go	go	VB
cord-324690-82qsirnk	27	4	-	-	HYPH
cord-324690-82qsirnk	27	5	no	no	DT
cord-324690-82qsirnk	27	6	-	-	HYPH
cord-324690-82qsirnk	27	7	go	go	JJ
cord-324690-82qsirnk	27	8	criteria	criterion	NNS
cord-324690-82qsirnk	27	9	for	for	IN
cord-324690-82qsirnk	27	10	advancement	advancement	NN
cord-324690-82qsirnk	27	11	met	meet	VBD
cord-324690-82qsirnk	27	12	,	,	,
cord-324690-82qsirnk	27	13	the	the	DT
cord-324690-82qsirnk	27	14	HVTN702	HVTN702	NNP
cord-324690-82qsirnk	27	15	study	study	NN
cord-324690-82qsirnk	27	16	moved	move	VBD
cord-324690-82qsirnk	27	17	ahead	ahead	RB
cord-324690-82qsirnk	27	18	.	.	.
cord-324690-82qsirnk	28	1	However	however	RB
cord-324690-82qsirnk	28	2	,	,	,
cord-324690-82qsirnk	28	3	no	no	DT
cord-324690-82qsirnk	28	4	protection	protection	NN
cord-324690-82qsirnk	28	5	was	be	VBD
cord-324690-82qsirnk	28	6	observed	observe	VBN
cord-324690-82qsirnk	28	7	,	,	,
cord-324690-82qsirnk	28	8	and	and	CC
cord-324690-82qsirnk	28	9	the	the	DT
cord-324690-82qsirnk	28	10	trial	trial	NN
cord-324690-82qsirnk	28	11	was	be	VBD
cord-324690-82qsirnk	28	12	terminated	terminate	VBN
cord-324690-82qsirnk	28	13	due	due	IN
cord-324690-82qsirnk	28	14	to	to	IN
cord-324690-82qsirnk	28	15	futility	futility	NN
cord-324690-82qsirnk	28	16	.	.	.
cord-324690-82qsirnk	29	1	While	while	IN
cord-324690-82qsirnk	29	2	the	the	DT
cord-324690-82qsirnk	29	3	field	field	NN
cord-324690-82qsirnk	29	4	is	be	VBZ
cord-324690-82qsirnk	29	5	disappointed	disappoint	VBN
cord-324690-82qsirnk	29	6	with	with	IN
cord-324690-82qsirnk	29	7	this	this	DT
cord-324690-82qsirnk	29	8	outcome	outcome	NN
cord-324690-82qsirnk	29	9	,	,	,
cord-324690-82qsirnk	29	10	it	-PRON-	PRP
cord-324690-82qsirnk	29	11	is	be	VBZ
cord-324690-82qsirnk	29	12	important	important	JJ
cord-324690-82qsirnk	29	13	to	to	TO
cord-324690-82qsirnk	29	14	understand	understand	VB
cord-324690-82qsirnk	29	15	the	the	DT
cord-324690-82qsirnk	29	16	possible	possible	JJ
cord-324690-82qsirnk	29	17	reasons	reason	NNS
cord-324690-82qsirnk	29	18	for	for	IN
cord-324690-82qsirnk	29	19	why	why	WRB
cord-324690-82qsirnk	29	20	this	this	DT
cord-324690-82qsirnk	29	21	occurred	occur	VBD
cord-324690-82qsirnk	29	22	.	.	.
cord-324690-82qsirnk	30	1	First	first	RB
cord-324690-82qsirnk	30	2	,	,	,
cord-324690-82qsirnk	30	3	there	there	EX
cord-324690-82qsirnk	30	4	were	be	VBD
cord-324690-82qsirnk	30	5	significant	significant	JJ
cord-324690-82qsirnk	30	6	differences	difference	NNS
cord-324690-82qsirnk	30	7	in	in	IN
cord-324690-82qsirnk	30	8	the	the	DT
cord-324690-82qsirnk	30	9	overall	overall	JJ
cord-324690-82qsirnk	30	10	incidence	incidence	NN
cord-324690-82qsirnk	30	11	between	between	IN
cord-324690-82qsirnk	30	12	the	the	DT
cord-324690-82qsirnk	30	13	study	study	NN
cord-324690-82qsirnk	30	14	cohorts	cohort	NNS
cord-324690-82qsirnk	30	15	in	in	IN
cord-324690-82qsirnk	30	16	HVTN702	HVTN702	NNP
cord-324690-82qsirnk	31	1	and	and	CC
cord-324690-82qsirnk	31	2	RV144	rv144	LS
cord-324690-82qsirnk	31	3	that	that	WDT
cord-324690-82qsirnk	31	4	could	could	MD
cord-324690-82qsirnk	31	5	have	have	VB
cord-324690-82qsirnk	31	6	overwhelmed	overwhelm	VBN
cord-324690-82qsirnk	31	7	a	a	DT
cord-324690-82qsirnk	31	8	modestly	modestly	RB
cord-324690-82qsirnk	31	9	protective	protective	JJ
cord-324690-82qsirnk	31	10	response	response	NN
cord-324690-82qsirnk	31	11	.	.	.
cord-324690-82qsirnk	32	1	Additionally	additionally	RB
cord-324690-82qsirnk	32	2	,	,	,
cord-324690-82qsirnk	32	3	it	-PRON-	PRP
cord-324690-82qsirnk	32	4	is	be	VBZ
cord-324690-82qsirnk	32	5	conceivable	conceivable	JJ
cord-324690-82qsirnk	32	6	that	that	IN
cord-324690-82qsirnk	32	7	the	the	DT
cord-324690-82qsirnk	32	8	correlates	correlate	NNS
cord-324690-82qsirnk	32	9	observed	observe	VBN
cord-324690-82qsirnk	32	10	in	in	IN
cord-324690-82qsirnk	32	11	RV144	RV144	NNP
cord-324690-82qsirnk	32	12	are	be	VBP
cord-324690-82qsirnk	32	13	specific	specific	JJ
cord-324690-82qsirnk	32	14	to	to	IN
cord-324690-82qsirnk	32	15	the	the	DT
cord-324690-82qsirnk	32	16	clades	clade	NNS
cord-324690-82qsirnk	32	17	and	and	CC
cord-324690-82qsirnk	32	18	population	population	NN
cord-324690-82qsirnk	32	19	in	in	IN
cord-324690-82qsirnk	32	20	Thailand	Thailand	NNP
cord-324690-82qsirnk	32	21	and	and	CC
cord-324690-82qsirnk	32	22	not	not	RB
cord-324690-82qsirnk	32	23	transferable	transferable	JJ
cord-324690-82qsirnk	32	24	to	to	IN
cord-324690-82qsirnk	32	25	the	the	DT
cord-324690-82qsirnk	32	26	Southern	Southern	NNP
cord-324690-82qsirnk	32	27	Africa	Africa	NNP
cord-324690-82qsirnk	32	28	epidemic	epidemic	NN
cord-324690-82qsirnk	32	29	.	.	.
cord-324690-82qsirnk	33	1	The	the	DT
cord-324690-82qsirnk	33	2	remaining	remain	VBG
cord-324690-82qsirnk	33	3	two	two	CD
cord-324690-82qsirnk	33	4	vaccine	vaccine	NN
cord-324690-82qsirnk	33	5	concepts	concept	NNS
cord-324690-82qsirnk	33	6	have	have	VBP
cord-324690-82qsirnk	33	7	reproducibly	reproducibly	RB
cord-324690-82qsirnk	33	8	demonstrated	demonstrate	VBN
cord-324690-82qsirnk	33	9	efficacy	efficacy	NN
cord-324690-82qsirnk	33	10	in	in	IN
cord-324690-82qsirnk	33	11	non	non	JJ
cord-324690-82qsirnk	33	12	-	-	JJ
cord-324690-82qsirnk	33	13	human	human	JJ
cord-324690-82qsirnk	33	14	primate	primate	JJ
cord-324690-82qsirnk	33	15	studies	study	NNS
cord-324690-82qsirnk	33	16	.	.	.
cord-324690-82qsirnk	34	1	The	the	DT
cord-324690-82qsirnk	34	2	most	most	RBS
cord-324690-82qsirnk	34	3	advanced	advanced	JJ
cord-324690-82qsirnk	34	4	concept	concept	NN
cord-324690-82qsirnk	34	5	is	be	VBZ
cord-324690-82qsirnk	34	6	currently	currently	RB
cord-324690-82qsirnk	34	7	being	be	VBG
cord-324690-82qsirnk	34	8	evaluated	evaluate	VBN
cord-324690-82qsirnk	34	9	in	in	IN
cord-324690-82qsirnk	34	10	two	two	CD
cord-324690-82qsirnk	34	11	studies	study	NNS
cord-324690-82qsirnk	34	12	,	,	,
cord-324690-82qsirnk	34	13	Imbokodo	Imbokodo	NNP
cord-324690-82qsirnk	34	14	(	(	-LRB-
cord-324690-82qsirnk	34	15	HVTN705	HVTN705	NNP
cord-324690-82qsirnk	34	16	/	/	SYM
cord-324690-82qsirnk	34	17	HPX2008	HPX2008	NNP
cord-324690-82qsirnk	34	18	)	)	-RRB-
cord-324690-82qsirnk	34	19	in	in	IN
cord-324690-82qsirnk	34	20	women	woman	NNS
cord-324690-82qsirnk	34	21	in	in	IN
cord-324690-82qsirnk	34	22	Southern	Southern	NNP
cord-324690-82qsirnk	34	23	Africa	Africa	NNP
cord-324690-82qsirnk	34	24	and	and	CC
cord-324690-82qsirnk	34	25	Mosaico	Mosaico	NNP
cord-324690-82qsirnk	34	26	(	(	-LRB-
cord-324690-82qsirnk	34	27	HVTN706	HVTN706	NNP
cord-324690-82qsirnk	34	28	/	/	SYM
cord-324690-82qsirnk	34	29	HPX3002	HPX3002	NNP
cord-324690-82qsirnk	34	30	)	)	-RRB-
cord-324690-82qsirnk	34	31	in	in	IN
cord-324690-82qsirnk	34	32	men	man	NNS
cord-324690-82qsirnk	34	33	and	and	CC
cord-324690-82qsirnk	34	34	transgender	transgender	NN
cord-324690-82qsirnk	34	35	persons	person	NNS
cord-324690-82qsirnk	34	36	who	who	WP
cord-324690-82qsirnk	34	37	have	have	VBP
cord-324690-82qsirnk	34	38	sex	sex	NN
cord-324690-82qsirnk	34	39	with	with	IN
cord-324690-82qsirnk	34	40	men	man	NNS
cord-324690-82qsirnk	34	41	in	in	IN
cord-324690-82qsirnk	34	42	the	the	DT
cord-324690-82qsirnk	34	43	Americas	Americas	NNPS
cord-324690-82qsirnk	34	44	and	and	CC
cord-324690-82qsirnk	34	45	Europe	Europe	NNP
cord-324690-82qsirnk	34	46	[	[	-LRB-
cord-324690-82qsirnk	34	47	8	8	CD
cord-324690-82qsirnk	34	48	]	]	-RRB-
cord-324690-82qsirnk	34	49	.	.	.
cord-324690-82qsirnk	35	1	Analysis	analysis	NN
cord-324690-82qsirnk	35	2	of	of	IN
cord-324690-82qsirnk	35	3	the	the	DT
cord-324690-82qsirnk	35	4	correlates	correlate	NNS
cord-324690-82qsirnk	35	5	of	of	IN
cord-324690-82qsirnk	35	6	protection	protection	NN
cord-324690-82qsirnk	35	7	seen	see	VBN
cord-324690-82qsirnk	35	8	in	in	IN
cord-324690-82qsirnk	35	9	the	the	DT
cord-324690-82qsirnk	35	10	non	non	JJ
cord-324690-82qsirnk	35	11	-	-	JJ
cord-324690-82qsirnk	35	12	human	human	JJ
cord-324690-82qsirnk	35	13	primate	primate	JJ
cord-324690-82qsirnk	35	14	studies	study	NNS
cord-324690-82qsirnk	35	15	point	point	VBP
cord-324690-82qsirnk	35	16	to	to	IN
cord-324690-82qsirnk	35	17	qualitatively	qualitatively	RB
cord-324690-82qsirnk	35	18	different	different	JJ
cord-324690-82qsirnk	35	19	responses	response	NNS
cord-324690-82qsirnk	35	20	than	than	IN
cord-324690-82qsirnk	35	21	those	those	DT
cord-324690-82qsirnk	35	22	observed	observe	VBN
cord-324690-82qsirnk	35	23	in	in	IN
cord-324690-82qsirnk	35	24	RV144	RV144	NNP
cord-324690-82qsirnk	35	25	,	,	,
cord-324690-82qsirnk	35	26	and	and	CC
cord-324690-82qsirnk	35	27	the	the	DT
cord-324690-82qsirnk	35	28	trials	trial	NNS
cord-324690-82qsirnk	35	29	are	be	VBP
cord-324690-82qsirnk	35	30	evaluating	evaluate	VBG
cord-324690-82qsirnk	35	31	in	in	IN
cord-324690-82qsirnk	35	32	silico	silico	NNS
cord-324690-82qsirnk	35	33	designed	design	VBN
cord-324690-82qsirnk	35	34	immunogens	immunogen	NNS
cord-324690-82qsirnk	35	35	to	to	TO
cord-324690-82qsirnk	35	36	present	present	VB
cord-324690-82qsirnk	35	37	the	the	DT
cord-324690-82qsirnk	35	38	most	most	RBS
cord-324690-82qsirnk	35	39	globally	globally	RB
cord-324690-82qsirnk	35	40	conserved	conserve	VBN
cord-324690-82qsirnk	35	41	HIV	HIV	NNP
cord-324690-82qsirnk	35	42	sequences	sequence	NNS
cord-324690-82qsirnk	35	43	to	to	TO
cord-324690-82qsirnk	35	44	trigger	trigger	VB
cord-324690-82qsirnk	35	45	quantitatively	quantitatively	RB
cord-324690-82qsirnk	35	46	superior	superior	JJ
cord-324690-82qsirnk	35	47	CD8	CD8	NNP
cord-324690-82qsirnk	35	48	+	+	CC
cord-324690-82qsirnk	35	49	T	T	NNP
cord-324690-82qsirnk	35	50	cell	cell	NN
cord-324690-82qsirnk	35	51	responses	response	NNS
cord-324690-82qsirnk	35	52	[	[	-LRB-
cord-324690-82qsirnk	35	53	8	8	CD
cord-324690-82qsirnk	35	54	,	,	,
cord-324690-82qsirnk	35	55	9	9	CD
cord-324690-82qsirnk	35	56	]	]	-RRB-
cord-324690-82qsirnk	35	57	.	.	.
cord-324690-82qsirnk	36	1	The	the	DT
cord-324690-82qsirnk	36	2	third	third	JJ
cord-324690-82qsirnk	36	3	approach	approach	NN
cord-324690-82qsirnk	36	4	,	,	,
cord-324690-82qsirnk	36	5	still	still	RB
cord-324690-82qsirnk	36	6	in	in	IN
cord-324690-82qsirnk	36	7	preclinical	preclinical	JJ
cord-324690-82qsirnk	36	8	studies	study	NNS
cord-324690-82qsirnk	36	9	,	,	,
cord-324690-82qsirnk	36	10	is	be	VBZ
cord-324690-82qsirnk	36	11	an	an	DT
cord-324690-82qsirnk	36	12	SIV	SIV	NNP
cord-324690-82qsirnk	36	13	vaccine	vaccine	NN
cord-324690-82qsirnk	36	14	delivered	deliver	VBN
cord-324690-82qsirnk	36	15	via	via	IN
cord-324690-82qsirnk	36	16	the	the	DT
cord-324690-82qsirnk	36	17	rhesus	rhesu	NNS
cord-324690-82qsirnk	36	18	cytomegalovirus	cytomegalovirus	NNP
cord-324690-82qsirnk	36	19	(	(	-LRB-
cord-324690-82qsirnk	36	20	RhCMV	RhCMV	NNP
cord-324690-82qsirnk	36	21	)	)	-RRB-
cord-324690-82qsirnk	36	22	vector	vector	NN
cord-324690-82qsirnk	36	23	platform	platform	NN
cord-324690-82qsirnk	36	24	.	.	.
cord-324690-82qsirnk	37	1	This	this	DT
cord-324690-82qsirnk	37	2	strategy	strategy	NN
cord-324690-82qsirnk	37	3	has	have	VBZ
cord-324690-82qsirnk	37	4	been	be	VBN
cord-324690-82qsirnk	37	5	shown	show	VBN
cord-324690-82qsirnk	37	6	by	by	IN
cord-324690-82qsirnk	37	7	Picker	Picker	NNP
cord-324690-82qsirnk	37	8	and	and	CC
cord-324690-82qsirnk	37	9	colleagues	colleague	NNS
cord-324690-82qsirnk	37	10	to	to	TO
cord-324690-82qsirnk	37	11	protect	protect	VB
cord-324690-82qsirnk	37	12	50	50	CD
cord-324690-82qsirnk	37	13	percent	percent	NN
cord-324690-82qsirnk	37	14	of	of	IN
cord-324690-82qsirnk	37	15	monkeys	monkey	NNS
cord-324690-82qsirnk	37	16	from	from	IN
cord-324690-82qsirnk	37	17	sustained	sustained	JJ
cord-324690-82qsirnk	37	18	infection	infection	NN
cord-324690-82qsirnk	37	19	[	[	-LRB-
cord-324690-82qsirnk	37	20	10	10	CD
cord-324690-82qsirnk	37	21	]	]	-RRB-
cord-324690-82qsirnk	37	22	.	.	.
cord-324690-82qsirnk	38	1	Efforts	effort	NNS
cord-324690-82qsirnk	38	2	are	be	VBP
cord-324690-82qsirnk	38	3	currently	currently	RB
cord-324690-82qsirnk	38	4	underway	underway	JJ
cord-324690-82qsirnk	38	5	to	to	TO
cord-324690-82qsirnk	38	6	transition	transition	VB
cord-324690-82qsirnk	38	7	to	to	IN
cord-324690-82qsirnk	38	8	a	a	DT
cord-324690-82qsirnk	38	9	human	human	JJ
cord-324690-82qsirnk	38	10	CMV	CMV	NNP
cord-324690-82qsirnk	38	11	vector	vector	NN
cord-324690-82qsirnk	38	12	platform	platform	NN
cord-324690-82qsirnk	38	13	with	with	IN
cord-324690-82qsirnk	38	14	Phase	phase	NN
cord-324690-82qsirnk	38	15	1	1	CD
cord-324690-82qsirnk	38	16	clinical	clinical	JJ
cord-324690-82qsirnk	38	17	trials	trial	NNS
cord-324690-82qsirnk	38	18	expected	expect	VBN
cord-324690-82qsirnk	38	19	in	in	IN
cord-324690-82qsirnk	38	20	2021	2021	CD
cord-324690-82qsirnk	38	21	.	.	.
cord-324690-82qsirnk	39	1	Although	although	IN
cord-324690-82qsirnk	39	2	humbled	humble	VBN
cord-324690-82qsirnk	39	3	by	by	IN
cord-324690-82qsirnk	39	4	the	the	DT
cord-324690-82qsirnk	39	5	outcome	outcome	NN
cord-324690-82qsirnk	39	6	of	of	IN
cord-324690-82qsirnk	39	7	HVTN702	HVTN702	NNP
cord-324690-82qsirnk	39	8	,	,	,
cord-324690-82qsirnk	39	9	we	-PRON-	PRP
cord-324690-82qsirnk	39	10	must	must	MD
cord-324690-82qsirnk	39	11	continue	continue	VB
cord-324690-82qsirnk	39	12	to	to	TO
cord-324690-82qsirnk	39	13	explore	explore	VB
cord-324690-82qsirnk	39	14	novel	novel	JJ
cord-324690-82qsirnk	39	15	methods	method	NNS
cord-324690-82qsirnk	39	16	of	of	IN
cord-324690-82qsirnk	39	17	inducing	induce	VBG
cord-324690-82qsirnk	39	18	or	or	CC
cord-324690-82qsirnk	39	19	providing	provide	VBG
cord-324690-82qsirnk	39	20	protective	protective	JJ
cord-324690-82qsirnk	39	21	immunity	immunity	NN
cord-324690-82qsirnk	39	22	against	against	IN
cord-324690-82qsirnk	39	23	HIV	HIV	NNP
cord-324690-82qsirnk	39	24	infection	infection	NN
cord-324690-82qsirnk	39	25	.	.	.
cord-324690-82qsirnk	40	1	One	one	CD
cord-324690-82qsirnk	40	2	of	of	IN
cord-324690-82qsirnk	40	3	the	the	DT
cord-324690-82qsirnk	40	4	most	most	RBS
cord-324690-82qsirnk	40	5	exciting	exciting	JJ
cord-324690-82qsirnk	40	6	developments	development	NNS
cord-324690-82qsirnk	40	7	in	in	IN
cord-324690-82qsirnk	40	8	HIV	HIV	NNP
cord-324690-82qsirnk	40	9	research	research	NN
cord-324690-82qsirnk	40	10	has	have	VBZ
cord-324690-82qsirnk	40	11	been	be	VBN
cord-324690-82qsirnk	40	12	the	the	DT
cord-324690-82qsirnk	40	13	ability	ability	NN
cord-324690-82qsirnk	40	14	to	to	TO
cord-324690-82qsirnk	40	15	isolate	isolate	VB
cord-324690-82qsirnk	40	16	and	and	CC
cord-324690-82qsirnk	40	17	produce	produce	VB
cord-324690-82qsirnk	40	18	broadly	broadly	RB
cord-324690-82qsirnk	40	19	neutralizing	neutralize	VBG
cord-324690-82qsirnk	40	20	monoclonal	monoclonal	JJ
cord-324690-82qsirnk	40	21	antibodies	antibody	NNS
cord-324690-82qsirnk	40	22	(	(	-LRB-
cord-324690-82qsirnk	40	23	bNAbs	bnabs	NN
cord-324690-82qsirnk	40	24	)	)	-RRB-
cord-324690-82qsirnk	40	25	that	that	WDT
cord-324690-82qsirnk	40	26	neutralize	neutralize	VBP
cord-324690-82qsirnk	40	27	nearly	nearly	RB
cord-324690-82qsirnk	40	28	all	all	DT
cord-324690-82qsirnk	40	29	of	of	IN
cord-324690-82qsirnk	40	30	circulating	circulate	VBG
cord-324690-82qsirnk	40	31	virus	virus	NN
cord-324690-82qsirnk	40	32	strains	strain	NNS
cord-324690-82qsirnk	40	33	from	from	IN
cord-324690-82qsirnk	40	34	all	all	DT
cord-324690-82qsirnk	40	35	clades	clade	NNS
cord-324690-82qsirnk	40	36	[	[	-LRB-
cord-324690-82qsirnk	40	37	11	11	CD
cord-324690-82qsirnk	40	38	,	,	,
cord-324690-82qsirnk	40	39	12	12	CD
cord-324690-82qsirnk	40	40	]	]	-RRB-
cord-324690-82qsirnk	40	41	.	.	.
cord-324690-82qsirnk	41	1	These	these	DT
cord-324690-82qsirnk	41	2	human	human	JJ
cord-324690-82qsirnk	41	3	antibodies	antibody	NNS
cord-324690-82qsirnk	41	4	prevent	prevent	VBP
cord-324690-82qsirnk	41	5	acquisition	acquisition	NN
cord-324690-82qsirnk	41	6	of	of	IN
cord-324690-82qsirnk	41	7	SHIV	SHIV	NNP
cord-324690-82qsirnk	41	8	infection	infection	NN
cord-324690-82qsirnk	41	9	,	,	,
cord-324690-82qsirnk	41	10	in	in	IN
cord-324690-82qsirnk	41	11	a	a	DT
cord-324690-82qsirnk	41	12	dose	dose	NN
cord-324690-82qsirnk	41	13	dependent	dependent	JJ
cord-324690-82qsirnk	41	14	manner	manner	NN
cord-324690-82qsirnk	41	15	,	,	,
cord-324690-82qsirnk	41	16	in	in	IN
cord-324690-82qsirnk	41	17	animal	animal	NN
cord-324690-82qsirnk	41	18	challenge	challenge	NN
cord-324690-82qsirnk	41	19	models	model	NNS
cord-324690-82qsirnk	41	20	and	and	CC
cord-324690-82qsirnk	41	21	when	when	WRB
cord-324690-82qsirnk	41	22	combinations	combination	NNS
cord-324690-82qsirnk	41	23	of	of	IN
cord-324690-82qsirnk	41	24	these	these	DT
cord-324690-82qsirnk	41	25	antibodies	antibody	NNS
cord-324690-82qsirnk	41	26	are	be	VBP
cord-324690-82qsirnk	41	27	used	use	VBN
cord-324690-82qsirnk	41	28	in	in	IN
cord-324690-82qsirnk	41	29	people	people	NNS
cord-324690-82qsirnk	41	30	living	live	VBG
cord-324690-82qsirnk	41	31	with	with	IN
cord-324690-82qsirnk	41	32	HIV	HIV	NNP
cord-324690-82qsirnk	41	33	,	,	,
cord-324690-82qsirnk	41	34	strong	strong	JJ
cord-324690-82qsirnk	41	35	antiviral	antiviral	JJ
cord-324690-82qsirnk	41	36	activity	activity	NN
cord-324690-82qsirnk	41	37	has	have	VBZ
cord-324690-82qsirnk	41	38	been	be	VBN
cord-324690-82qsirnk	41	39	demonstrated	demonstrate	VBN
cord-324690-82qsirnk	41	40	.	.	.
cord-324690-82qsirnk	42	1	The	the	DT
cord-324690-82qsirnk	42	2	Antibody	Antibody	NNP
cord-324690-82qsirnk	42	3	Mediated	Mediated	NNP
cord-324690-82qsirnk	42	4	Protection	Protection	NNP
cord-324690-82qsirnk	42	5	(	(	-LRB-
cord-324690-82qsirnk	42	6	AMP	AMP	NNP
cord-324690-82qsirnk	42	7	)	)	-RRB-
cord-324690-82qsirnk	42	8	trials	trial	NNS
cord-324690-82qsirnk	42	9	are	be	VBP
cord-324690-82qsirnk	42	10	currently	currently	RB
cord-324690-82qsirnk	42	11	evaluating	evaluate	VBG
cord-324690-82qsirnk	42	12	VRC01	VRC01	NNP
cord-324690-82qsirnk	42	13	,	,	,
cord-324690-82qsirnk	42	14	the	the	DT
cord-324690-82qsirnk	42	15	CD4	CD4	NNP
cord-324690-82qsirnk	42	16	binding	bind	VBG
cord-324690-82qsirnk	42	17	site	site	NN
cord-324690-82qsirnk	42	18	targeted	target	VBN
cord-324690-82qsirnk	42	19	bNAb	bNAb	''
cord-324690-82qsirnk	42	20	,	,	,
cord-324690-82qsirnk	42	21	to	to	TO
cord-324690-82qsirnk	42	22	determine	determine	VB
cord-324690-82qsirnk	42	23	the	the	DT
cord-324690-82qsirnk	42	24	ability	ability	NN
cord-324690-82qsirnk	42	25	of	of	IN
cord-324690-82qsirnk	42	26	this	this	DT
cord-324690-82qsirnk	42	27	single	single	JJ
cord-324690-82qsirnk	42	28	antibody	antibody	NN
cord-324690-82qsirnk	42	29	to	to	TO
cord-324690-82qsirnk	42	30	prevent	prevent	VB
cord-324690-82qsirnk	42	31	HIV	HIV	NNP
cord-324690-82qsirnk	42	32	infection	infection	NN
cord-324690-82qsirnk	42	33	in	in	IN
cord-324690-82qsirnk	42	34	women	woman	NNS
cord-324690-82qsirnk	42	35	in	in	IN
cord-324690-82qsirnk	42	36	Southern	Southern	NNP
cord-324690-82qsirnk	42	37	Africa	Africa	NNP
cord-324690-82qsirnk	42	38	and	and	CC
cord-324690-82qsirnk	42	39	MSM	MSM	NNP
cord-324690-82qsirnk	42	40	and	and	CC
cord-324690-82qsirnk	42	41	transgender	transgender	NN
cord-324690-82qsirnk	42	42	persons	person	NNS
cord-324690-82qsirnk	42	43	in	in	IN
cord-324690-82qsirnk	42	44	the	the	DT
cord-324690-82qsirnk	42	45	Americas	Americas	NNPS
cord-324690-82qsirnk	42	46	[	[	-LRB-
cord-324690-82qsirnk	42	47	13	13	CD
cord-324690-82qsirnk	42	48	]	]	-RRB-
cord-324690-82qsirnk	42	49	.	.	.
cord-324690-82qsirnk	43	1	The	the	DT
cord-324690-82qsirnk	43	2	AMP	AMP	NNP
cord-324690-82qsirnk	43	3	studies	study	NNS
cord-324690-82qsirnk	43	4	have	have	VBP
cord-324690-82qsirnk	43	5	not	not	RB
cord-324690-82qsirnk	43	6	been	be	VBN
cord-324690-82qsirnk	43	7	impacted	impact	VBN
cord-324690-82qsirnk	43	8	by	by	IN
cord-324690-82qsirnk	43	9	COVID-19	COVID-19	NNP
cord-324690-82qsirnk	43	10	,	,	,
cord-324690-82qsirnk	43	11	and	and	CC
cord-324690-82qsirnk	43	12	results	result	VBZ
cord-324690-82qsirnk	43	13	from	from	IN
cord-324690-82qsirnk	43	14	the	the	DT
cord-324690-82qsirnk	43	15	AMP	AMP	NNP
cord-324690-82qsirnk	43	16	studies	study	NNS
cord-324690-82qsirnk	43	17	are	be	VBP
cord-324690-82qsirnk	43	18	expected	expect	VBN
cord-324690-82qsirnk	43	19	in	in	IN
cord-324690-82qsirnk	43	20	fall	fall	NN
cord-324690-82qsirnk	43	21	of	of	IN
cord-324690-82qsirnk	43	22	2020	2020	CD
cord-324690-82qsirnk	43	23	.	.	.
cord-324690-82qsirnk	44	1	If	if	IN
cord-324690-82qsirnk	44	2	protection	protection	NN
cord-324690-82qsirnk	44	3	is	be	VBZ
cord-324690-82qsirnk	44	4	observed	observe	VBN
cord-324690-82qsirnk	44	5	in	in	IN
cord-324690-82qsirnk	44	6	the	the	DT
cord-324690-82qsirnk	44	7	AMP	AMP	NNP
cord-324690-82qsirnk	44	8	trials	trial	NNS
cord-324690-82qsirnk	44	9	,	,	,
cord-324690-82qsirnk	44	10	an	an	DT
cord-324690-82qsirnk	44	11	important	important	JJ
cord-324690-82qsirnk	44	12	correlate	correlate	NN
cord-324690-82qsirnk	44	13	for	for	IN
cord-324690-82qsirnk	44	14	future	future	JJ
cord-324690-82qsirnk	44	15	vaccine	vaccine	NN
cord-324690-82qsirnk	44	16	studies	study	NNS
cord-324690-82qsirnk	44	17	will	will	MD
cord-324690-82qsirnk	44	18	be	be	VB
cord-324690-82qsirnk	44	19	established	establish	VBN
cord-324690-82qsirnk	44	20	.	.	.
cord-324690-82qsirnk	45	1	In	in	IN
cord-324690-82qsirnk	45	2	the	the	DT
cord-324690-82qsirnk	45	3	meantime	meantime	NN
cord-324690-82qsirnk	45	4	,	,	,
cord-324690-82qsirnk	45	5	efforts	effort	NNS
cord-324690-82qsirnk	45	6	are	be	VBP
cord-324690-82qsirnk	45	7	underway	underway	JJ
cord-324690-82qsirnk	45	8	to	to	TO
cord-324690-82qsirnk	45	9	define	define	VB
cord-324690-82qsirnk	45	10	immunogens	immunogen	NNS
cord-324690-82qsirnk	45	11	that	that	IN
cord-324690-82qsirnk	45	12	specifically	specifically	RB
cord-324690-82qsirnk	45	13	trigger	trigger	VB
cord-324690-82qsirnk	45	14	neutralizing	neutralize	VBG
cord-324690-82qsirnk	45	15	antibodies	antibody	NNS
cord-324690-82qsirnk	45	16	by	by	IN
cord-324690-82qsirnk	45	17	targeting	target	VBG
cord-324690-82qsirnk	45	18	five	five	CD
cord-324690-82qsirnk	45	19	specific	specific	JJ
cord-324690-82qsirnk	45	20	epitopes	epitope	NNS
cord-324690-82qsirnk	45	21	,	,	,
cord-324690-82qsirnk	45	22	which	which	WDT
cord-324690-82qsirnk	45	23	are	be	VBP
cord-324690-82qsirnk	45	24	unique	unique	JJ
cord-324690-82qsirnk	45	25	sites	site	NNS
cord-324690-82qsirnk	45	26	of	of	IN
cord-324690-82qsirnk	45	27	vulnerability	vulnerability	NN
cord-324690-82qsirnk	45	28	on	on	IN
cord-324690-82qsirnk	45	29	the	the	DT
cord-324690-82qsirnk	45	30	HIV	HIV	NNP
cord-324690-82qsirnk	45	31	Env	Env	NNP
cord-324690-82qsirnk	45	32	trimer	trimer	NN
cord-324690-82qsirnk	45	33	glycoprotein	glycoprotein	NN
cord-324690-82qsirnk	45	34	[	[	-LRB-
cord-324690-82qsirnk	45	35	12	12	CD
cord-324690-82qsirnk	45	36	,	,	,
cord-324690-82qsirnk	45	37	14	14	CD
cord-324690-82qsirnk	45	38	]	]	-RRB-
cord-324690-82qsirnk	45	39	.	.	.
cord-324690-82qsirnk	46	1	The	the	DT
cord-324690-82qsirnk	46	2	goal	goal	NN
cord-324690-82qsirnk	46	3	is	be	VBZ
cord-324690-82qsirnk	46	4	to	to	TO
cord-324690-82qsirnk	46	5	create	create	VB
cord-324690-82qsirnk	46	6	a	a	DT
cord-324690-82qsirnk	46	7	discrete	discrete	JJ
cord-324690-82qsirnk	46	8	set	set	NN
cord-324690-82qsirnk	46	9	of	of	IN
cord-324690-82qsirnk	46	10	immunogens	immunogen	NNS
cord-324690-82qsirnk	46	11	that	that	WDT
cord-324690-82qsirnk	46	12	can	can	MD
cord-324690-82qsirnk	46	13	reproducibly	reproducibly	RB
cord-324690-82qsirnk	46	14	elicit	elicit	VB
cord-324690-82qsirnk	46	15	the	the	DT
cord-324690-82qsirnk	46	16	production	production	NN
cord-324690-82qsirnk	46	17	of	of	IN
cord-324690-82qsirnk	46	18	neutralizing	neutralize	VBG
cord-324690-82qsirnk	46	19	antibody	antibody	NN
cord-324690-82qsirnk	46	20	responses	response	NNS
cord-324690-82qsirnk	46	21	against	against	IN
cord-324690-82qsirnk	46	22	two	two	CD
cord-324690-82qsirnk	46	23	or	or	CC
cord-324690-82qsirnk	46	24	more	more	JJR
cord-324690-82qsirnk	46	25	of	of	IN
cord-324690-82qsirnk	46	26	these	these	DT
cord-324690-82qsirnk	46	27	target	target	NN
cord-324690-82qsirnk	46	28	sites	site	NNS
cord-324690-82qsirnk	46	29	.	.	.
cord-324690-82qsirnk	47	1	The	the	DT
cord-324690-82qsirnk	47	2	Collaborative	Collaborative	NNP
cord-324690-82qsirnk	47	3	HIV	HIV	NNP
cord-324690-82qsirnk	47	4	Immunogen	Immunogen	NNP
cord-324690-82qsirnk	47	5	Project	Project	NNP
cord-324690-82qsirnk	47	6	[	[	-LRB-
cord-324690-82qsirnk	47	7	12	12	CD
cord-324690-82qsirnk	47	8	]	]	-RRB-
cord-324690-82qsirnk	47	9	is	be	VBZ
cord-324690-82qsirnk	47	10	seeking	seek	VBG
cord-324690-82qsirnk	47	11	to	to	TO
cord-324690-82qsirnk	47	12	prospectively	prospectively	RB
cord-324690-82qsirnk	47	13	design	design	VB
cord-324690-82qsirnk	47	14	and	and	CC
cord-324690-82qsirnk	47	15	select	select	VB
cord-324690-82qsirnk	47	16	the	the	DT
cord-324690-82qsirnk	47	17	optimal	optimal	JJ
cord-324690-82qsirnk	47	18	combination	combination	NN
cord-324690-82qsirnk	47	19	of	of	IN
cord-324690-82qsirnk	47	20	immunogens	immunogen	NNS
cord-324690-82qsirnk	47	21	to	to	TO
cord-324690-82qsirnk	47	22	be	be	VB
cord-324690-82qsirnk	47	23	evaluated	evaluate	VBN
cord-324690-82qsirnk	47	24	for	for	IN
cord-324690-82qsirnk	47	25	the	the	DT
cord-324690-82qsirnk	47	26	induction	induction	NN
cord-324690-82qsirnk	47	27	of	of	IN
cord-324690-82qsirnk	47	28	broad	broad	JJ
cord-324690-82qsirnk	47	29	neutralization	neutralization	NN
cord-324690-82qsirnk	47	30	of	of	IN
cord-324690-82qsirnk	47	31	a	a	DT
cord-324690-82qsirnk	47	32	range	range	NN
cord-324690-82qsirnk	47	33	of	of	IN
cord-324690-82qsirnk	47	34	HIV	HIV	NNP
cord-324690-82qsirnk	47	35	isolates	isolate	VBZ
cord-324690-82qsirnk	47	36	.	.	.
cord-324690-82qsirnk	48	1	As	as	IN
cord-324690-82qsirnk	48	2	we	-PRON-	PRP
cord-324690-82qsirnk	48	3	reflect	reflect	VBP
cord-324690-82qsirnk	48	4	on	on	IN
cord-324690-82qsirnk	48	5	HIV	HIV	NNP
cord-324690-82qsirnk	48	6	Vaccine	Vaccine	NNP
cord-324690-82qsirnk	48	7	Awareness	Awareness	NNP
cord-324690-82qsirnk	48	8	Day	Day	NNP
cord-324690-82qsirnk	48	9	and	and	CC
cord-324690-82qsirnk	48	10	recent	recent	JJ
cord-324690-82qsirnk	48	11	developments	development	NNS
cord-324690-82qsirnk	48	12	in	in	IN
cord-324690-82qsirnk	48	13	the	the	DT
cord-324690-82qsirnk	48	14	vaccine	vaccine	NN
cord-324690-82qsirnk	48	15	field	field	NN
cord-324690-82qsirnk	48	16	,	,	,
cord-324690-82qsirnk	48	17	it	-PRON-	PRP
cord-324690-82qsirnk	48	18	is	be	VBZ
cord-324690-82qsirnk	48	19	clear	clear	JJ
cord-324690-82qsirnk	48	20	that	that	IN
cord-324690-82qsirnk	48	21	much	much	JJ
cord-324690-82qsirnk	48	22	work	work	NN
cord-324690-82qsirnk	48	23	remains	remain	VBZ
cord-324690-82qsirnk	48	24	to	to	TO
cord-324690-82qsirnk	48	25	be	be	VB
cord-324690-82qsirnk	48	26	done	do	VBN
cord-324690-82qsirnk	48	27	.	.	.
cord-324690-82qsirnk	49	1	Going	go	VBG
cord-324690-82qsirnk	49	2	forward	forward	RB
cord-324690-82qsirnk	49	3	we	-PRON-	PRP
cord-324690-82qsirnk	49	4	must	must	MD
cord-324690-82qsirnk	49	5	continue	continue	VB
cord-324690-82qsirnk	49	6	to	to	TO
cord-324690-82qsirnk	49	7	engage	engage	VB
cord-324690-82qsirnk	49	8	community	community	NN
cord-324690-82qsirnk	49	9	to	to	TO
cord-324690-82qsirnk	49	10	ensure	ensure	VB
cord-324690-82qsirnk	49	11	a	a	DT
cord-324690-82qsirnk	49	12	shared	share	VBN
cord-324690-82qsirnk	49	13	understanding	understanding	NN
cord-324690-82qsirnk	49	14	of	of	IN
cord-324690-82qsirnk	49	15	our	-PRON-	PRP$
cord-324690-82qsirnk	49	16	common	common	JJ
cord-324690-82qsirnk	49	17	goals	goal	NNS
cord-324690-82qsirnk	49	18	.	.	.
cord-324690-82qsirnk	50	1	While	while	IN
cord-324690-82qsirnk	50	2	we	-PRON-	PRP
cord-324690-82qsirnk	50	3	pursue	pursue	VBP
cord-324690-82qsirnk	50	4	a	a	DT
cord-324690-82qsirnk	50	5	safe	safe	JJ
cord-324690-82qsirnk	50	6	and	and	CC
cord-324690-82qsirnk	50	7	effective	effective	JJ
cord-324690-82qsirnk	50	8	HIV	HIV	NNP
cord-324690-82qsirnk	50	9	vaccine	vaccine	NN
cord-324690-82qsirnk	50	10	,	,	,
cord-324690-82qsirnk	50	11	we	-PRON-	PRP
cord-324690-82qsirnk	50	12	are	be	VBP
cord-324690-82qsirnk	50	13	also	also	RB
cord-324690-82qsirnk	50	14	seeking	seek	VBG
cord-324690-82qsirnk	50	15	ways	way	NNS
cord-324690-82qsirnk	50	16	of	of	IN
cord-324690-82qsirnk	50	17	improving	improve	VBG
cord-324690-82qsirnk	50	18	chemoprophylaxis	chemoprophylaxis	NNP
cord-324690-82qsirnk	50	19	.	.	.
cord-324690-82qsirnk	51	1	We	-PRON-	PRP
cord-324690-82qsirnk	51	2	remain	remain	VBP
cord-324690-82qsirnk	51	3	optimistic	optimistic	JJ
cord-324690-82qsirnk	51	4	that	that	IN
cord-324690-82qsirnk	51	5	effective	effective	JJ
cord-324690-82qsirnk	51	6	interventions	intervention	NNS
cord-324690-82qsirnk	51	7	that	that	WDT
cord-324690-82qsirnk	51	8	people	people	NNS
cord-324690-82qsirnk	51	9	will	will	MD
cord-324690-82qsirnk	51	10	reliably	reliably	RB
cord-324690-82qsirnk	51	11	use	use	VB
cord-324690-82qsirnk	51	12	can	can	MD
cord-324690-82qsirnk	51	13	be	be	VB
cord-324690-82qsirnk	51	14	developed	develop	VBN
cord-324690-82qsirnk	51	15	and	and	CC
cord-324690-82qsirnk	51	16	brought	bring	VBN
cord-324690-82qsirnk	51	17	to	to	TO
cord-324690-82qsirnk	51	18	scale	scale	VB
cord-324690-82qsirnk	51	19	.	.	.
cord-324690-82qsirnk	52	1	On	on	IN
cord-324690-82qsirnk	52	2	HIV	HIV	NNP
cord-324690-82qsirnk	52	3	Vaccine	Vaccine	NNP
cord-324690-82qsirnk	52	4	Awareness	Awareness	NNP
cord-324690-82qsirnk	52	5	Day	Day	NNP
cord-324690-82qsirnk	52	6	,	,	,
cord-324690-82qsirnk	52	7	let	let	VB
cord-324690-82qsirnk	52	8	us	-PRON-	PRP
cord-324690-82qsirnk	52	9	pause	pause	VB
cord-324690-82qsirnk	52	10	and	and	CC
cord-324690-82qsirnk	52	11	reflect	reflect	VB
cord-324690-82qsirnk	52	12	on	on	IN
cord-324690-82qsirnk	52	13	how	how	WRB
cord-324690-82qsirnk	52	14	far	far	RB
cord-324690-82qsirnk	52	15	we	-PRON-	PRP
cord-324690-82qsirnk	52	16	have	have	VBP
cord-324690-82qsirnk	52	17	come	come	VBN
cord-324690-82qsirnk	52	18	while	while	IN
cord-324690-82qsirnk	52	19	continuing	continue	VBG
cord-324690-82qsirnk	52	20	to	to	TO
cord-324690-82qsirnk	52	21	focus	focus	VB
cord-324690-82qsirnk	52	22	on	on	IN
cord-324690-82qsirnk	52	23	completing	complete	VBG
cord-324690-82qsirnk	52	24	the	the	DT
cord-324690-82qsirnk	52	25	work	work	NN
cord-324690-82qsirnk	52	26	needed	need	VBN
cord-324690-82qsirnk	52	27	to	to	TO
cord-324690-82qsirnk	52	28	achieve	achieve	VB
cord-324690-82qsirnk	52	29	an	an	DT
cord-324690-82qsirnk	52	30	effective	effective	JJ
cord-324690-82qsirnk	52	31	vaccine	vaccine	NN
cord-324690-82qsirnk	52	32	.	.	.
cord-324690-82qsirnk	53	1	The	the	DT
cord-324690-82qsirnk	53	2	authors	author	NNS
cord-324690-82qsirnk	53	3	collaboratively	collaboratively	RB
cord-324690-82qsirnk	53	4	conceived	conceive	VBD
cord-324690-82qsirnk	53	5	the	the	DT
cord-324690-82qsirnk	53	6	content	content	NN
cord-324690-82qsirnk	53	7	of	of	IN
cord-324690-82qsirnk	53	8	the	the	DT
cord-324690-82qsirnk	53	9	paper	paper	NN
cord-324690-82qsirnk	53	10	.	.	.
cord-324690-82qsirnk	54	1	CWD	CWD	NNP
cord-324690-82qsirnk	54	2	wrote	write	VBD
cord-324690-82qsirnk	54	3	the	the	DT
cord-324690-82qsirnk	54	4	first	first	JJ
cord-324690-82qsirnk	54	5	draft	draft	NN
cord-324690-82qsirnk	54	6	and	and	CC
cord-324690-82qsirnk	54	7	ASF	ASF	NNP
cord-324690-82qsirnk	54	8	edited	edit	VBD
cord-324690-82qsirnk	54	9	the	the	DT
cord-324690-82qsirnk	54	10	manuscript	manuscript	NN
cord-324690-82qsirnk	54	11	into	into	IN
cord-324690-82qsirnk	54	12	this	this	DT
cord-324690-82qsirnk	54	13	final	final	JJ
cord-324690-82qsirnk	54	14	form	form	NN
cord-324690-82qsirnk	54	15	.	.	.
cord-324690-82qsirnk	55	1	The	the	DT
cord-324690-82qsirnk	55	2	authors	author	NNS
cord-324690-82qsirnk	55	3	thank	thank	VBP
cord-324690-82qsirnk	55	4	the	the	DT
cord-324690-82qsirnk	55	5	trial	trial	NN
cord-324690-82qsirnk	55	6	participants	participant	NNS
cord-324690-82qsirnk	55	7	,	,	,
cord-324690-82qsirnk	55	8	community	community	NN
cord-324690-82qsirnk	55	9	members	member	NNS
cord-324690-82qsirnk	55	10	,	,	,
cord-324690-82qsirnk	55	11	activists	activist	NNS
cord-324690-82qsirnk	55	12	and	and	CC
cord-324690-82qsirnk	55	13	researchers	researcher	NNS
cord-324690-82qsirnk	55	14	who	who	WP
cord-324690-82qsirnk	55	15	have	have	VBP
cord-324690-82qsirnk	55	16	so	so	RB
cord-324690-82qsirnk	55	17	willingly	willingly	RB
cord-324690-82qsirnk	55	18	participated	participate	VBN
cord-324690-82qsirnk	55	19	in	in	IN
cord-324690-82qsirnk	55	20	the	the	DT
cord-324690-82qsirnk	55	21	challenging	challenging	JJ
cord-324690-82qsirnk	55	22	work	work	NN
cord-324690-82qsirnk	55	23	of	of	IN
cord-324690-82qsirnk	55	24	HIV	HIV	NNP
cord-324690-82qsirnk	55	25	vaccine	vaccine	NN
cord-324690-82qsirnk	55	26	discovery	discovery	NN
cord-324690-82qsirnk	55	27	and	and	CC
cord-324690-82qsirnk	55	28	development	development	NN
cord-324690-82qsirnk	55	29	.	.	.
cord-324690-82qsirnk	56	1	The	the	DT
cord-324690-82qsirnk	56	2	authors	author	NNS
cord-324690-82qsirnk	56	3	also	also	RB
cord-324690-82qsirnk	56	4	thank	thank	VBP
cord-324690-82qsirnk	56	5	Robert	Robert	NNP
cord-324690-82qsirnk	56	6	Gulakowski	Gulakowski	NNP
cord-324690-82qsirnk	56	7	,	,	,
cord-324690-82qsirnk	56	8	Thomas	Thomas	NNP
cord-324690-82qsirnk	56	9	Liang	Liang	NNP
cord-324690-82qsirnk	56	10	,	,	,
cord-324690-82qsirnk	56	11	Mary	Mary	NNP
cord-324690-82qsirnk	56	12	Marovich	Marovich	NNP
cord-324690-82qsirnk	56	13	and	and	CC
cord-324690-82qsirnk	56	14	Sarah	Sarah	NNP
cord-324690-82qsirnk	56	15	Read	Read	VBD
cord-324690-82qsirnk	56	16	for	for	IN
cord-324690-82qsirnk	56	17	their	-PRON-	PRP$
cord-324690-82qsirnk	56	18	careful	careful	JJ
cord-324690-82qsirnk	56	19	review	review	NN
cord-324690-82qsirnk	56	20	and	and	CC
cord-324690-82qsirnk	56	21	comments	comment	NNS
cord-324690-82qsirnk	56	22	on	on	IN
cord-324690-82qsirnk	56	23	this	this	DT
cord-324690-82qsirnk	56	24	manuscript	manuscript	NN
cord-324690-82qsirnk	56	25	.	.	.
cord-324690-82qsirnk	57	1	Overview	Overview	NNP
cord-324690-82qsirnk	57	2	of	of	IN
cord-324690-82qsirnk	57	3	STEP	step	NN
cord-324690-82qsirnk	57	4	and	and	CC
cord-324690-82qsirnk	57	5	Phambili	Phambili	NNP
cord-324690-82qsirnk	57	6	trial	trial	NN
cord-324690-82qsirnk	57	7	results	result	NNS
cord-324690-82qsirnk	57	8	:	:	:
cord-324690-82qsirnk	58	1	two	two	CD
cord-324690-82qsirnk	58	2	phase	phase	NN
cord-324690-82qsirnk	58	3	IIb	iib	JJ
cord-324690-82qsirnk	58	4	test	test	NN
cord-324690-82qsirnk	58	5	-	-	HYPH
cord-324690-82qsirnk	58	6	of	of	IN
cord-324690-82qsirnk	58	7	-	-	HYPH
cord-324690-82qsirnk	58	8	concept	concept	NN
cord-324690-82qsirnk	58	9	studies	study	NNS
cord-324690-82qsirnk	58	10	investigating	investigate	VBG
cord-324690-82qsirnk	58	11	the	the	DT
cord-324690-82qsirnk	58	12	efficacy	efficacy	NN
cord-324690-82qsirnk	58	13	of	of	IN
cord-324690-82qsirnk	58	14	MRK	MRK	NNP
cord-324690-82qsirnk	58	15	adenovirus	adenovirus	NN
cord-324690-82qsirnk	58	16	type	type	NN
cord-324690-82qsirnk	58	17	5	5	CD
cord-324690-82qsirnk	58	18	gag	gag	NN
cord-324690-82qsirnk	58	19	/	/	SYM
cord-324690-82qsirnk	58	20	pol	pol	NN
cord-324690-82qsirnk	58	21	/	/	SYM
cord-324690-82qsirnk	58	22	nef	nef	NNP
cord-324690-82qsirnk	58	23	subtype	subtype	NN
cord-324690-82qsirnk	58	24	B	B	NNP
cord-324690-82qsirnk	58	25	HIV	HIV	NNP
cord-324690-82qsirnk	58	26	vaccine	vaccine	NN
cord-324690-82qsirnk	58	27	HIV	HIV	NNP
cord-324690-82qsirnk	58	28	vaccine	vaccine	NN
cord-324690-82qsirnk	58	29	research	research	NN
cord-324690-82qsirnk	58	30	:	:	:
cord-324690-82qsirnk	58	31	the	the	DT
cord-324690-82qsirnk	58	32	way	way	NN
cord-324690-82qsirnk	58	33	forward	forward	RB
cord-324690-82qsirnk	58	34	Vaccination	vaccination	NN
cord-324690-82qsirnk	58	35	with	with	IN
cord-324690-82qsirnk	58	36	ALVAC	ALVAC	NNP
cord-324690-82qsirnk	58	37	and	and	CC
cord-324690-82qsirnk	58	38	AIDSVAX	AIDSVAX	NNP
cord-324690-82qsirnk	58	39	to	to	TO
cord-324690-82qsirnk	58	40	prevent	prevent	VB
cord-324690-82qsirnk	58	41	HIV-1	HIV-1	NNP
cord-324690-82qsirnk	58	42	infection	infection	NN
cord-324690-82qsirnk	58	43	in	in	IN
cord-324690-82qsirnk	58	44	Thailand	Thailand	NNP
cord-324690-82qsirnk	58	45	Immune	Immune	NNP
cord-324690-82qsirnk	58	46	-	-	HYPH
cord-324690-82qsirnk	58	47	correlates	correlate	VBZ
cord-324690-82qsirnk	58	48	analysis	analysis	NN
cord-324690-82qsirnk	58	49	of	of	IN
cord-324690-82qsirnk	58	50	an	an	DT
cord-324690-82qsirnk	58	51	HIV-1	HIV-1	NNP
cord-324690-82qsirnk	58	52	vaccine	vaccine	NN
cord-324690-82qsirnk	58	53	efficacy	efficacy	NN
cord-324690-82qsirnk	58	54	trial	trial	NN
cord-324690-82qsirnk	58	55	Subtype	Subtype	NNP
cord-324690-82qsirnk	58	56	C	C	NNP
cord-324690-82qsirnk	58	57	ALVAC	ALVAC	NNP
cord-324690-82qsirnk	58	58	-	-	HYPH
cord-324690-82qsirnk	58	59	HIV	HIV	NNP
cord-324690-82qsirnk	58	60	and	and	CC
cord-324690-82qsirnk	58	61	bivalent	bivalent	JJ
cord-324690-82qsirnk	58	62	subtype	subtype	NN
cord-324690-82qsirnk	58	63	C	C	NNP
cord-324690-82qsirnk	58	64	gp120	gp120	NNP
cord-324690-82qsirnk	58	65	/	/	SYM
cord-324690-82qsirnk	58	66	MF59	MF59	NNP
cord-324690-82qsirnk	58	67	HIV-1	HIV-1	NNP
cord-324690-82qsirnk	58	68	vaccine	vaccine	NN
cord-324690-82qsirnk	58	69	in	in	IN
cord-324690-82qsirnk	58	70	low	low	JJ
cord-324690-82qsirnk	58	71	-	-	HYPH
cord-324690-82qsirnk	58	72	risk	risk	NN
cord-324690-82qsirnk	58	73	,	,	,
cord-324690-82qsirnk	58	74	HIV	HIV	NNP
cord-324690-82qsirnk	58	75	-	-	HYPH
cord-324690-82qsirnk	58	76	uninfected	uninfected	JJ
cord-324690-82qsirnk	58	77	,	,	,
cord-324690-82qsirnk	58	78	South	south	JJ
cord-324690-82qsirnk	58	79	African	african	JJ
cord-324690-82qsirnk	58	80	adults	adult	NNS
cord-324690-82qsirnk	58	81	:	:	:
cord-324690-82qsirnk	58	82	a	a	DT
cord-324690-82qsirnk	58	83	phase	phase	NN
cord-324690-82qsirnk	58	84	1/2	1/2	CD
cord-324690-82qsirnk	58	85	trial	trial	NN
cord-324690-82qsirnk	58	86	Safety	safety	NN
cord-324690-82qsirnk	58	87	and	and	CC
cord-324690-82qsirnk	58	88	immune	immune	JJ
cord-324690-82qsirnk	58	89	responses	response	NNS
cord-324690-82qsirnk	58	90	after	after	IN
cord-324690-82qsirnk	58	91	a	a	DT
cord-324690-82qsirnk	58	92	12-month	12-month	JJ
cord-324690-82qsirnk	58	93	booster	booster	NN
cord-324690-82qsirnk	58	94	in	in	IN
cord-324690-82qsirnk	58	95	healthy	healthy	JJ
cord-324690-82qsirnk	58	96	HIV	HIV	NNP
cord-324690-82qsirnk	58	97	-	-	HYPH
cord-324690-82qsirnk	58	98	uninfected	uninfected	JJ
cord-324690-82qsirnk	58	99	adults	adult	NNS
cord-324690-82qsirnk	58	100	in	in	IN
cord-324690-82qsirnk	58	101	HVTN	HVTN	NNP
cord-324690-82qsirnk	58	102	100	100	CD
cord-324690-82qsirnk	58	103	in	in	IN
cord-324690-82qsirnk	58	104	South	South	NNP
cord-324690-82qsirnk	58	105	Africa	Africa	NNP
cord-324690-82qsirnk	58	106	:	:	:
cord-324690-82qsirnk	59	1	A	a	DT
cord-324690-82qsirnk	59	2	randomized	randomized	JJ
cord-324690-82qsirnk	59	3	double	double	JJ
cord-324690-82qsirnk	59	4	-	-	HYPH
cord-324690-82qsirnk	59	5	blind	blind	JJ
cord-324690-82qsirnk	59	6	placebocontrolled	placebocontrolled	JJ
cord-324690-82qsirnk	59	7	trial	trial	NN
cord-324690-82qsirnk	59	8	of	of	IN
cord-324690-82qsirnk	59	9	ALVAC	ALVAC	NNP
cord-324690-82qsirnk	59	10	-	-	HYPH
cord-324690-82qsirnk	59	11	HIV	HIV	NNP
cord-324690-82qsirnk	59	12	(	(	-LRB-
cord-324690-82qsirnk	59	13	vCP2438	vcp2438	LS
cord-324690-82qsirnk	59	14	)	)	-RRB-
cord-324690-82qsirnk	59	15	and	and	CC
cord-324690-82qsirnk	59	16	bivalent	bivalent	JJ
cord-324690-82qsirnk	59	17	subtype	subtype	NN
cord-324690-82qsirnk	60	1	C	C	NNP
cord-324690-82qsirnk	60	2	gp120	gp120	NNP
cord-324690-82qsirnk	60	3	/	/	SYM
cord-324690-82qsirnk	60	4	MF59	MF59	NNP
cord-324690-82qsirnk	60	5	vaccines	vaccine	NNS
cord-324690-82qsirnk	61	1	Immune	immune	JJ
cord-324690-82qsirnk	61	2	correlates	correlate	NNS
cord-324690-82qsirnk	61	3	of	of	IN
cord-324690-82qsirnk	61	4	the	the	DT
cord-324690-82qsirnk	61	5	Thai	Thai	NNP
cord-324690-82qsirnk	61	6	RV144	RV144	NNP
cord-324690-82qsirnk	61	7	HIV	HIV	NNP
cord-324690-82qsirnk	61	8	vaccine	vaccine	NN
cord-324690-82qsirnk	61	9	regimen	regimen	NN
cord-324690-82qsirnk	61	10	in	in	IN
cord-324690-82qsirnk	61	11	South	South	NNP
cord-324690-82qsirnk	61	12	Africa	Africa	NNP
cord-324690-82qsirnk	61	13	Evaluation	Evaluation	NNP
cord-324690-82qsirnk	61	14	of	of	IN
cord-324690-82qsirnk	61	15	a	a	DT
cord-324690-82qsirnk	61	16	mosaic	mosaic	JJ
cord-324690-82qsirnk	61	17	HIV-1	HIV-1	NNP
cord-324690-82qsirnk	61	18	vaccine	vaccine	NN
cord-324690-82qsirnk	61	19	in	in	IN
cord-324690-82qsirnk	61	20	a	a	DT
cord-324690-82qsirnk	61	21	multicentre	multicentre	NNP
cord-324690-82qsirnk	61	22	,	,	,
cord-324690-82qsirnk	61	23	randomised	randomised	JJ
cord-324690-82qsirnk	61	24	,	,	,
cord-324690-82qsirnk	61	25	double	double	JJ
cord-324690-82qsirnk	61	26	-	-	HYPH
cord-324690-82qsirnk	61	27	blind	blind	JJ
cord-324690-82qsirnk	61	28	,	,	,
cord-324690-82qsirnk	61	29	placebo	placebo	NN
cord-324690-82qsirnk	61	30	-	-	HYPH
cord-324690-82qsirnk	61	31	controlled	control	VBN
cord-324690-82qsirnk	61	32	,	,	,
cord-324690-82qsirnk	61	33	phase	phase	NN
cord-324690-82qsirnk	61	34	1/2a	1/2a	JJ
cord-324690-82qsirnk	61	35	clinical	clinical	JJ
cord-324690-82qsirnk	61	36	trial	trial	NN
cord-324690-82qsirnk	61	37	(	(	-LRB-
cord-324690-82qsirnk	61	38	APPROACH	APPROACH	NNP
cord-324690-82qsirnk	61	39	)	)	-RRB-
cord-324690-82qsirnk	61	40	and	and	CC
cord-324690-82qsirnk	61	41	in	in	IN
cord-324690-82qsirnk	61	42	rhesus	rhesu	NNS
cord-324690-82qsirnk	61	43	monkeys	monkey	NNS
cord-324690-82qsirnk	62	1	(	(	-LRB-
cord-324690-82qsirnk	62	2	NHP	NHP	NNP
cord-324690-82qsirnk	62	3	13	13	CD
cord-324690-82qsirnk	62	4	-	-	SYM
cord-324690-82qsirnk	62	5	19	19	CD
cord-324690-82qsirnk	62	6	)	)	-RRB-
cord-324690-82qsirnk	62	7	Increased	increase	VBN
cord-324690-82qsirnk	62	8	valency	valency	NN
cord-324690-82qsirnk	62	9	of	of	IN
cord-324690-82qsirnk	62	10	conserved	conserved	JJ
cord-324690-82qsirnk	62	11	-	-	HYPH
cord-324690-82qsirnk	62	12	mosaic	mosaic	NN
cord-324690-82qsirnk	62	13	vaccines	vaccine	NNS
cord-324690-82qsirnk	62	14	enhances	enhance	VBZ
cord-324690-82qsirnk	62	15	the	the	DT
cord-324690-82qsirnk	62	16	breadth	breadth	NN
cord-324690-82qsirnk	62	17	and	and	CC
cord-324690-82qsirnk	62	18	depth	depth	NN
cord-324690-82qsirnk	62	19	of	of	IN
cord-324690-82qsirnk	62	20	epitope	epitope	NN
cord-324690-82qsirnk	62	21	recognition	recognition	NN
cord-324690-82qsirnk	63	1	A	a	DT
cord-324690-82qsirnk	63	2	live	live	RB
cord-324690-82qsirnk	63	3	-	-	HYPH
cord-324690-82qsirnk	63	4	attenuated	attenuated	JJ
cord-324690-82qsirnk	63	5	RhCMV	RhCMV	NNP
cord-324690-82qsirnk	63	6	/	/	SYM
cord-324690-82qsirnk	63	7	SIV	SIV	NNP
cord-324690-82qsirnk	63	8	vaccine	vaccine	NN
cord-324690-82qsirnk	63	9	shows	show	VBZ
cord-324690-82qsirnk	63	10	long	long	JJ
cord-324690-82qsirnk	63	11	-	-	HYPH
cord-324690-82qsirnk	63	12	term	term	NN
cord-324690-82qsirnk	63	13	efficacy	efficacy	NN
cord-324690-82qsirnk	63	14	against	against	IN
cord-324690-82qsirnk	63	15	heterologous	heterologous	JJ
cord-324690-82qsirnk	63	16	SIV	SIV	NNP
cord-324690-82qsirnk	63	17	challenge	challenge	NN
cord-324690-82qsirnk	63	18	Use	Use	NNP
cord-324690-82qsirnk	63	19	of	of	IN
cord-324690-82qsirnk	63	20	broadly	broadly	RB
cord-324690-82qsirnk	63	21	neutralizing	neutralize	VBG
cord-324690-82qsirnk	63	22	antibodies	antibody	NNS
cord-324690-82qsirnk	63	23	for	for	IN
cord-324690-82qsirnk	63	24	HIV-1	HIV-1	NNP
cord-324690-82qsirnk	63	25	prevention	prevention	NN
cord-324690-82qsirnk	63	26	Multiple	multiple	JJ
cord-324690-82qsirnk	63	27	roles	role	NNS
cord-324690-82qsirnk	63	28	for	for	IN
cord-324690-82qsirnk	63	29	HIV	HIV	NNP
cord-324690-82qsirnk	63	30	broadly	broadly	RB
cord-324690-82qsirnk	63	31	neutralizing	neutralize	VBG
cord-324690-82qsirnk	63	32	antibodies	antibody	NNS
cord-324690-82qsirnk	63	33	Safety	Safety	NNP
cord-324690-82qsirnk	63	34	,	,	,
cord-324690-82qsirnk	63	35	pharmacokinetics	pharmacokinetic	NNS
cord-324690-82qsirnk	63	36	and	and	CC
cord-324690-82qsirnk	63	37	neutralization	neutralization	NN
cord-324690-82qsirnk	63	38	of	of	IN
cord-324690-82qsirnk	63	39	the	the	DT
cord-324690-82qsirnk	63	40	broadly	broadly	RB
cord-324690-82qsirnk	63	41	neutralizing	neutralize	VBG
cord-324690-82qsirnk	63	42	HIV-1	HIV-1	NNP
cord-324690-82qsirnk	63	43	human	human	JJ
cord-324690-82qsirnk	63	44	monoclonal	monoclonal	JJ
cord-324690-82qsirnk	63	45	antibody	antibody	NN
cord-324690-82qsirnk	63	46	VRC01	VRC01	NNP
cord-324690-82qsirnk	63	47	in	in	IN
cord-324690-82qsirnk	63	48	healthy	healthy	JJ
cord-324690-82qsirnk	63	49	adults	adult	NNS
cord-324690-82qsirnk	63	50	HIV-1	HIV-1	NNP
cord-324690-82qsirnk	63	51	neutralizing	neutralize	VBG
cord-324690-82qsirnk	63	52	antibody	antibody	NN
cord-324690-82qsirnk	63	53	signatures	signature	NNS
cord-324690-82qsirnk	63	54	and	and	CC
cord-324690-82qsirnk	63	55	application	application	NN
cord-324690-82qsirnk	63	56	to	to	IN
cord-324690-82qsirnk	63	57	epitope	epitope	NN
cord-324690-82qsirnk	63	58	-	-	HYPH
cord-324690-82qsirnk	63	59	targeted	target	VBN
cord-324690-82qsirnk	63	60	vaccine	vaccine	NN
cord-324690-82qsirnk	63	61	design	design	NN